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Abstract 
Background: Gram-negative resistance is a growing problem worldwide. It is generally 
believed that rates of resistant bacteria within a hospital are a function of antibiotic use, 
resistant organisms brought into the hospital, infection control efforts, and underlying 
severity of patient illness. The relative contribution of each to a particular resistance 
phenotype is unclear. P. aeruginosa is responsible for many hospital acquired infections 
and it may become resistant to carbapenems.  In addition, newer threats to the future 
utility of the carbapenems are carbapenemase-producing K. pneumoniae  
Purpose:   To determine if there is an association between the volume and composition 
of antibiotic use, geography, severity of illness and rates of carbapenem-resistant P. 
aeruginosa and K. pneumoniae.  
Methods:  This is a retrospective ecological longitudinal investigation within the 
University HealthSystem Consortium affiliated academic medical centers. Antibiotic use 
data between January 1, 2006 and December 31, 2009 were obtained from billing 
records and reported as days of therapy per 1000 patient days (DOT/1000 PD), in 
addition to hospital characteristics (e.g. geographical location, bed size, case mix 
index).  “Whole house” antibiograms were obtained to determine rates and proportions 
of carbapenem-resistant P. aeruginosa (CR-PA) and carbapenem resistant K. 
pneumoniae (CR-KP).  Also, CR-KP isolation was generated as a binary outcome. 
Generalized estimating equations (GEE) were used to model CR-KP and CR-PA.  
Results:  CR-KP rates (1000PDs) increased from 0.07 in 2006 to 0.15 in 2009 (P= 
0.0118) and CR-KP proportions increased from 1.3% in 2006 to 3.1% in 2009 (0.0003) 
xii 
 
within 40 hospitals over 2006-2009.  However, CR-PA rates and proportions were stable 
over the same period.  Geographical location, carbapenems use, and antipseudomonal 
penicillins use were significantly associated with CR-KP isolation. Thus, for every ten 
DOT/1000 PDs increase in carbapenem use, the odds of CR-KP isolation increased by 
42% (P=0.0149).  In contrast, for every ten DOT/1000 PDs increase in antipseudomonal 
penicillin use, the odds of CR-KP isolation decreased by 14%.  However, there was no 
significant model to explain CR-PA rates and proportions. 
Conclusion:  Carbapenems, antipseudomonal penicillins, and geographical location 
were identified as risk factors associated with CR-KP isolation. These findings 
emphasize the challenges associated with the treatment of multidrug- gram-negative 
bacteria.
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CHAPTER 1 
Introduction 
 
1.1 Overview of the document  
 
This dissertation describes a study designed to explain carbapenem resistant gram-
negative bacteria in a consortium of academic medical health centers located across 
the U.S. Antimicrobial drug use, severity of illness, and hospital demographics were 
investigated as potential predictors of carbapenem-resistant P. aeruginosa (CR-PA) and 
carbapenem resistant K. pneumoniae (CR-KP).  This chapter provides background 
information necessary to understand the significance of this project. The second chapter 
reviews the available literature and provides more extensive background from previous 
investigations; including epidemiology CR-PA and CR-KP, previously described risk 
factors, and confounding factors. Chapter 3 describes the methodology used for the 
dissertation project. The results are provided in Chapter 4, followed by a discussion and 
concluding remarks in Chapter 5. 
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1.2 Background 
 
Multidrug-resistant gram negative bacteria 
The antimicrobial drug resistance problem is increasing in the U.S. and worldwide. This 
issue is getting more complicated because of two factors: emergence of multidrug-
resistance (MDR) gram-negative organisms; and the shortage of new, effective 
treatment options against these resistant bacteria.[1-8]  The current situation is 
demanding new methods to improve antibiotic drug use in the clinical setting.  
Antimicrobial Stewardship Programs (ASPs) are evolving all over the United States 
hospitals; their mission is to improve the quality of antibiotic use, treatment outcomes, 
and cost.[9- 12]  This is valuable as antibiotic use at both the patient- and aggregate- 
level has been shown to play a major role in bacterial resistance.[13-16]  In addition, the 
relationship between antibiotic use and bacterial resistance is further complicated by 
patient risk factors and infection control measures which vary among health care 
settings. [15, 17]  The composition of patients within each hospital varies from one 
hospital to another.  Severely ill patients will presumably be at greater risk to develop 
infections caused by resistant organisms; because they have impaired host defenses 
and will receive more antibiotics compared to low risk patients.  
Carbapenem antibiotics  
Despite the increase in resistance rates against many beta-lactams, carbapenem 
antibiotics still retain activity against most organisms and are considered the drug of 
choice against extended-spectrum beta-lactams (ESBLs) producing 
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Enterobacteriaceae, such as E. coli and K. pneumoniae. [18-20]  Thus, developing 
resistance against this class of antibiotics is considered a serious problem since the 
remaining options, colistin or tigecycline, are more toxic and possibly less effective.[21] 
Moreover, infections with carbapenem resistant gram-negative organisms are 
associated with high rates of mortality and cost.[22-24]   
Carbapenem-resistant gram negative bacteria 
Carbapenem-resistant Klebsiella pneumoniae (CR-KP) is of special concern because of 
its rapid spread, microbiological detection challenges, poor health outcomes, and it is 
resistant to most antimicrobials.[25-29]  Outbreaks of Klebsiella pneumoniae 
carbapenamase (KPC)-producing Enterobacteriaceae have been reported in the U.S. 
(with geographical variation) and all over the world. [30-35]  According to the Centers for 
Disease Control and Prevention (CDC), KPC has been reported in 35 states in the U.S. 
in 2010 compared to one state in 2001.[36]  In addition, carbapenem-resistant P. 
aeruginosa (CR-PA) is often a multi-drug resistance bacteria that is associated with 
significant health outcomes and difficult to be treated with complete eradication.[37,38] 
Cofounding in Pharmacoepidemiology 
Any epidemiologic investigation attempting to describe the relationship between an 
exposure and an outcome must consider potential confounders. Confounding occurs 
when a certain variable(s) influence the relationship between an exposure and 
outcome.[39]  The presence of confounding can result in overestimation of the 
association of the true association, underestimation of the true association, or change in 
the direction of the association.[40]  Therefore, it is imperative to identify confounders 
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and control for them. In most situations, confounders are identified in advance based on 
previous investigations or expert knowledge.[39,40] Severity of illness, hospital bed 
size, and geographical location were identified as confounders.[15, 16, 41]  
Multivariable modeling is one way to control for confounders at the level of statistical 
analysis. [42] 
Previous investigations 
Prior antibiotic use (carbapenems, fluoroquinolones, and extended-spectrum 
cephalosporins) and certain patient risk factors (e.g. ICU admission, mechanical 
ventilation, length of hospitalization) were found to be independent risk factors 
associated with CR-KP in several single centered case-control studies.[22,29,42-44] 
These studies were of small sample size, not geographically distributed across the 
nation which limit their generalizability.  In addition, prior carbapenem use and other 
patient factors (e.g. Foley catheters transfer from outside facility, mechanical ventilation) 
were identified as independent risk factors associated with CR-PA in case-control 
studies.[23,24,45,46]  One multicenter study did not find an association between 
carbapenem use and CR-PA in a model that is not adjusting for hospital 
demographics.[47] 
Preliminary results 
The preliminary results reported trends in hospital antibacterial drug use in adult 
patients from 22 US academic medical centers, all of which participated in UHC 
programs. A significant finding was that broad-spectrum antibiotic use is increasing, in 
part due to an overall increase in carbapenem use.[48] Also, using the same set of 
hospitals they found that hospitals which restrict carbapenem antibiotic use (e.g. 
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imipenem, meropenem) actually use less carbapenem, and rates of CR-Pa are 
significantly lower.[ 49] 
1.3 Purpose 
 
This study investigated carbapenem-resistance gram-negative bacteria: Pseudomonas 
aeruginosa and Klebsiella pneumoniae. The purpose of this investigation is to assess 
how different “patterns” of antimicrobial drug use, severity of illness, and geography to 
different patterns of carbapenem resistance. The hypothesis is that a significant portion 
of the between-hospital variability in rates of CR-PA and CR-KP can be explained by 
the combination of antimicrobial drug use, severity of illness, and hospital demographics  
 
1.4 Objectives 
 
1- Determine trends and patterns of overall gram-negative antibacterial drug use 
over the study period (2006-2009). 
2- Determine proportions, rates, and trends of resistance among CR-PA at each of 
the participating hospitals during the study period. 
3- Determine proportions, rates, and trends of resistance among CR-KP at each of 
the participating hospitals during the study period. Also, identify clinical 
microbiology practices related to the isolation of these organisms.  
4- Develop a model to determine the magnitude and the significance of association 
between the use of specific antibiotics, severity of illness, geography, and 
carbapenem-resistant gram-negative bacteria (CR-PA and CR-KP).  
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  1.5 Significance and practical implications 
 
The preliminary data, as well as data from others, suggest that carbapenem antibiotic 
use and other antibiotic use might be risk factors for CR-PA and CR-KP, but this 
relationship is complex.  Also, there are no investigations at a national level that have 
examined at the role of antibacterial drug use in CR-KP in geographically distributed 
hospitals.  It is important to understand the relationships between antibiotic use, patient 
composition, infection control, and carbapenem resistance to overcome the burden of 
these resistant pathogens, especially, with the paucity of new antimicrobial drugs. This 
study is the first multicenter study that attempted to assess the impact of aggregate 
antibiotic use and other predictors on CR-KP in a relatively large sample of U.S. 
academic medical centers. This investigation extend previous investigations of CR-PA 
by adjusting for important hospital characteristics (e.g. geographical location, bed size) 
The contribution with this study is the assessment of CR-PA and CR-KP current status 
and associated risk factors in U.S. academic health centers. If modifiable risk factors 
such as, antibiotic use was identified, this could serve as a target of intervention for 
antimicrobial stewardship programs to improve resistance patterns in hospitals. In 
addition, this investigation could provide hypotheses to conduct further studies, such as 
quasi- experiments to assess the effect of the potential modifiable factors on resistance 
and to establish a causal relationship, if any. 
 
  
7 
 
CHAPTER 2 
Literature Review 
 
2.1 Multidrug-resistant gram-negative bacteria and antimicrobial drug 
use 
 
The selection of antibiotic-resistant bacteria has major consequences at both the 
patient-and hospital-level. It would increase the risk of colonized patients to develop a 
true clinical infection and increase the risk of cross-transmission among hospitalized 
patients and further spread of resistance in the community.[ 4,50]  While antibiotic 
resistance may develop in the absence of antibiotic pressure, antimicrobial usage has 
been identified as one of the most important risk factors driving the development of 
resistance in many studies.[16]  Both overuse of a restricted number of antibiotic agents 
and homogeneous use raise the effect of selection pressure.[4, 16]  However, data to 
support the preceding ‘beliefs’ are few and the existing data are primarily restricted to 
single institutions.[13]   
Multidrug-resistant (MDR) gram-negative bacteria are often defined as ones that are 
resistant to three or more classes of antibiotics through different mechanisms.[1, 2, 4] 
The molecular mechanism of multidrug resistance is complicated. The selection 
pressure imposed by the use of one antibiotic can result in the selection of bacteria 
resistant not only to that particular antibiotic but to other antibiotics, by co-resistance 
and cross-resistance mechanisms.[50,51]  Mechanisms of acquired resistance include: 
gene mutations resulting in altered porin channels limiting penetration of the antibiotic 
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into the bacterial cell; production of enzymes that inactivate the antibiotic; alteration of 
the target site for the antibiotic; or formation of efflux pumps extruding the antibiotic from 
the cell interior before it can act on its target.[52]  One example is the overuse of 
fluoroquinolone agents, which had led to development of aggressive resistance 
mechanisms such as “upregulated efflux pumps” in P. aeruginosa which was resistant 
not only to fluoroquinolones but also carbapenems (so-called collateral damage).[51,53]  
Actually, all classes of antibiotics except polymyxins are susceptible to extrusion by any 
of these efflux systems.[54]   
For gram-negative organisms, the impact of infection control measures seems to be 
less effective than antibiotic-control measures when compared to gram-positive 
organisms such as methicillin-resistant S.aureus (MRSA); thus, the relative contribution 
of infection control in nosocomial gram-negative bacteria remains more 
controversial.[55]  The clinical epidemiology of resistant bacteria may alter over time. 
For example, one study found prior fluoroquinolone use to be associated with 
fluoroquinolone-resistant E. coli colonization in a relationship that varied significantly by 
the study year.[56]  Interventions to improve hospital antibiotic use were associated with 
a decline in the incidence of antimicrobial resistant bacteria.[57]  However, this may 
differ substantially across institutions due to the variability of the composition of 
patients.[58] 
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2.2 Measures of bacterial resistance 
 
Schwaber et al. has argued that the use of proportions of resistant organisms to 
evaluate the influence of antibacterial use on resistance can be misleading and 
biased.[59]  Proportions are dependent on the susceptible and resistant bacteria 
populations, whereas the incidence rate of resistance depends only upon the resistant 
population. He further explained that antibiotic use likely leads to a decrease in the 
absolute number of susceptible organisms, which results in an increase in the 
proportion of isolates that are resistant in a certain population.  However, this does not 
necessarily reflect an increase in the absolute number of resistant isolates or the burden 
of resistance.[59]  One investigation looking at the impact of ciprofloxacin restriction on 
both proportion and incidence rates of resistant isolates of P. aeruginosa found that 
ciprofloxacin use declined by 57% and both incidence rates and the proportion of 
ciprofloxacin-resistant P. aeruginosa isolates declined significantly. [60]  In contrast, 
another investigation reported that the incidence rates of MRSA bacteremia in patients 
with central lines from 1,684 U.S. intensive care units decreased by nearly 50% over the 
10-year period 1997 to 2007, while the proportion (percent) increased by 25%.[61]  
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2.3 Carbapenem-resistant P. aeruginosa: status and implications 
 
Overview 
 P. aeruginosa is a gram-negative rod that is considered to be one of the leading causes 
of nosocomial (hospital acquired) infections including healthcare associated pneumonia 
and ventilator associated pneumonia. [62,63]  Carbapenem antibiotics (e.g. imipenem, 
meropenem, and doripenem) continue to be the most consistent effective agents in the 
treatment of P. aeruginosa infections. However, it is often difficult to treat P. aeruginosa 
with complete eradication due to its ability to develop resistance to multiple classes of 
antibacterial drugs, including carbapenems, in the process of treating an existing 
infection.[64,65]   
Multidrug-resistant P. aeruginosa 
Multidrug-resistant P. aeruginosa is often defined as resistance to three or more classes 
of antibiotics through different mechanisms including production of beta-lactamases, 
upregulation of multidrug efflux pumps, and cell wall mutations. Up-regulated efflux can 
concurrently compromise fluoroquinolones and most beta-lactams leaving only 
aminoglycosides and carbapenems susceptible, although the latter have high 
mutational frequency.  A combination of up-regulated efflux, loss of OprD, and 
impermeability to aminoglycosides compromise all class of antibiotics except the 
polymyxins.[66]  Infections with MDR P. aeruginosa are associated with an increase in 
rates of morbidity, mortality, the need for surgical intervention, length of hospital stay, 
and overall cost of treatment.[67-69] 
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Current status 
The Surveillance Network Database USA showed an increase in the proportion of P. 
aeruginosa isolates that are resistant to multiple antibiotics over the period 1997-2000. 
Sixteen percent of these isolates are resistant to ≥ 3 antipseudomonal agents 
(imipenem, amikacin, ceftazidime, ciprofloxacin, gentamicin, and piperacillin-
tazobactam). [66]   According to the National Nosocomial Infection Surveillance System 
(NNIS), the rates of imipenem-resistant P. aeruginosa associated with nosocomial 
infections increased by 15% between 1998 and 2002.[70]  In contrast, a 2009 report of 
10 year trends in antimicrobial susceptibility among 10-15 U.S. hospitals contributing to 
the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) surveillance 
project found that susceptibility to carbapenems for P. aeruginosa has not changed.[71]  
12 
 
2.4 Carbapenem-resistant K. pneumoniae: status and implications 
 
K. pneumoniae is a gram-negative, facultative anaerobic bacillus that is responsible for 
many infections including urinary tract infections, pneumonia, bloodstream infections, 
and intra-abdominal infections. Resistance to penicillin, cephalosporin, and 
fluoroquinolone antibiotics has become more common among these organisms over the 
years. Resistance to extended-spectrum cephalosporins, which occurs through the 
production of ESBLs, has been described worldwide for the past twenty years.[62,63]  
Carbapenems have been the most important antimicrobial class for the treatment of 
these organisms especially with the increasing incidence of fluoroquinolone resistance 
among Enterobacteriaceae including K. pneumoniae, and they are the drug of choice to 
treat serious infections caused by ESBLs. [5, 7] 
The two most important phenotypes of carbapenem-resistant Enterobacteriaceae in 
particular for this investigation in K. pneumoniae are the production of the serine-
carbapenemase (KPC) and the metallo-beta-lactamase VIM.[3]  Until recently, 
resistance to carbapenems has been uncommon among K. pneumoniae in the United 
States. However, the emergence of KPC and an Ambler molecular class A enzyme that 
utilizes serine at the active site and thereby is able to hydrolyze carbapenems and all 
other beta- lactam antibiotics have led to the increased prevalence of carbapenem-
resistant K. pneumoniae in the U.S.[21]  Klebsiella pneumoniae carbapenemase are 
encoded by the gene blaKPC, whose potential for inter-species and geographic 
dissemination is principally explained by its location within a Tn3-type transposon, 
Tn4401. This transposon is a genetic element which is able of inserting into various 
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plasmids of gram-negative bacteria. Plasmids carrying blaKPC are frequently 
associated with resistance determinants for other antibiotics. [26, 27]  Although KPCs 
are identified in many gram-negative species, K. pneumoniae is the predominant 
species carrying this enzyme.[26]  The second common mechanism after KPC is the 
production of metallo-beta-lactamnases of ambler class. Acquired metallo-beta-
lactamases (MBLs) most commonly IMP- and VIM-type, are zinc-dependent enzymes 
that have been of growing concern over the last decade. This is due to their capacity to 
readily hydrolyze most of the beta-lactam antibiotics, including carbapenems, and their 
increasing dissemination among gram-negative pathogens.[72] 
Another mechanism associated with carbapenem resistance in K. pneumoniae is the 
loss of one or both of the porins OmpK35 and OmpK36. Loss of OmpK35 or OmpK36 
may increase the MICs of carbapenems, and if the strain also produces beta-
lactamases and carbapenemases, it may result in carbapenem resistance.[73,74] 
The first KPC-producing K. pneumoniae isolate was reported in North Carolina in 2001. 
Afterwards, outbreaks and transmission of KPC-producing organisms were reported in 
the U.S. with geographical variations, as the northeastern part of the nation had several 
outbreaks.[30-32]  The initial outbreaks were located in New York City. In one 
surveillance study conducted in hospitals in Brooklyn in 2003, out of 602 K. pneumoniae 
isolates identified a total of 3.3% were found to carry blaKPC.  In the next year, two 
hospitals in the same city reported outbreaks with an increased number of carbapenem-
resistant K. pneumoniae. [30]   Later on, KPC-producing bacteria have spread 
throughout the U.S. and worldwide [33-35].  According to CDC, KPC-producing bacteria 
have been reported in 35 states in the U.S. in 2010 compared to one state in 2001.[36]  
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Moreover, 8% of all Klebsiella isolates reported to CDC at 2008 were resistant to 
carbapenems compared to less than 1% in 2000. [28] Further, the National Healthcare 
Safety Network (NHSN) data from 2006 through 2007 reported the percentage of K. 
pneumoniae isolates that were resistant to carbapenems by infection type: central 
venous catheter associated bloodstream infection (10.8%); catheter associated urinary 
tract infection (10.1%); surgical site infection (5.2%); and ventilator associated 
pneumonia (3.6%).[75]  In the same MYSTIC surveillance project report mentioned in 
section 2.3, the incidence of CR-KP was shown to decline in 2008 compared to the 
steep increase in resistance rates observed from 2004 to 2007. [71] 
2.5 Clinical outcomes and treatment options of carbapenem-resistant 
K. pneumoniae  
 
The spread of KPCs has become a significant problem due to poor outcomes such as, 
increased cost, length of hospitalization, frequent treatment failure, and high mortality 
rates (30%-57%).[22, 28,29]  Poor outcomes resulting from clinical infections with KPC-
producing bacteria have been reported since the first outbreaks in New York City 
hospitals.[30] In one retrospective cohort study, 44% of CR-KP patients died, whereas 
12.5% of carbapenem-susceptible K. pneumoniae patients died. Also, CR-KP isolation 
was identified as an independent predictor of in-hospital mortality.[42]  Another cohort 
study found that KPC-producing K. pneumoniae cases were associated with a greater 
than two fold increased risk of death when compared to susceptible K. pneumoniae 
cases.[22] 
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In addition to poor outcomes associated with KPC-producing K. pneumoniae, treatment 
options are very limited. Clinicians are becoming more dependent on polymyxins, and 
tigecycline for the treatment of these infections.[76]  One literature review, found that 
treatment with aminoglycosides, polymyxins combinations, and tigecycline had higher 
rates of success compared to carbapenem and polymyxin monotherapy which had 
lower rates of success.[77]  Polymyxins are in the class of cyclic polypeptides 
antibiotics; polymyxin B and E (colistin) are available in the market.  In vitro 
susceptibility of KPC-producing isolates to polymyxins is 90-100 %. Polymyxin use is 
infrequent; mainly because of their associated neurotoxicity and nephrotoxicty.[27, 77] 
Combining polymyxins with other antibiotics in treating KPC-producing isolates has 
been associated with a better success rate.  In one study, 25% of patients treated with 
polymyxin monotherapy developed resistance during treatment, whereas none of the 
patients treated with a polymyxin-tigecycline combination developed resistance.[78] 
Tigecycline is a novel semisynthetic glycylcycline, which is used in the treatment of 
severe infections caused by multidrug-resistant gram-negative bacteria including KPC- 
producing bacteria. [21, 27]  Although in vitro susceptibilities of KPC-producing bacteria 
are 100% against tigecycline, treatment failure has been reported. According to one 
literature review, five out of seven patients were treated successfully with tigecycline. 
One case of recurrent infection was associated with a tigecycline MIC increase from 0.5 
to 2 mg/L.  However, tigecycline has low serum concentrations and urine 
concentrations. [26] 
Aminoglycosides are considered valuable therapeutic options for treating KPC-
producing bacteria, but resistance is increasing towards these agents; susceptibility 
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should be always evaluated, and preferably these agents should be used in 
combination. [26, 27] 
 2.6 Detection of carbapenemase-producing K. pneumoniae  
 
Detection of KPCs by the microbiology laboratory represents a challenge as they may 
not be detected by routine antibiotic susceptibility testing methods. [21, 25, 27]  A 
number of KPC-producing bacteria have been reported as susceptible to carbapenems 
as they have carbapenem MICs that remain in the susceptible range.[21, 25]  The 
presence of KPC does not always result in high-level resistance to carbapenems, but 
may represent MIC elevations that stay within the susceptible or intermediate range.[77] 
Experts consider detection of KPC-producing bacteria susceptibility to be difficult with 
any microbiological technique.[21]  Detection of KPC using automatic antibiotic 
susceptibility testing methods was shown to provide inconsistent results and considered 
problematic. Hence, more complicated, confirmatory, and phenotypic methods are 
needed to confirm KPC.  Confirmatory methods include: modified Hodge test; 
polymerase chain reaction (PCR); inhibitor based test; EDTA-based synergy tests; and 
Etests.[25, 77, 79-83]  The gold standard method to confirm the presence of a KPC is 
spectrophotometry followed by PCR of the blaKPC gene.[21, 77]  However, this method 
is time consuming, costly, and requires reference laboratories to verify results.[21,77]  
Susceptibility testing of KPC-producing bacteria using Etest method is considered 
difficult to interpret as the scattered inner colonies can make the inhibition zone difficult 
to read.[21, 77, 79]  Modified Hodge test has high sensitivity (95%-100%) to detect 
diffusible carbapenemase and it’s the only method recommended by the Clinical 
17 
 
Laboratory Standards Institute (CLSI) in 2009 to confirm KPC-producing bacteria. [84]  
That is, for an Enterobacteriaceae with elevated MICs to carbapenems (2 -4 µg/mL) or a 
reduced disk diffusion zone, it should be tested with MHT to confirm 
carbapenemases.[84]  The test is performed by culturing susceptible isolates on a 
Mueller-Hinton plate. Then the carbapenem disk is placed in the center, and isolates 
suspected of producing carbapenemases are streaked from the disk to the outer margin 
of the plate. Growth of bacteria like K. pneumoniae near the disk or along the isolate 
streak indicates the presence of carbapenamases (figure 2.1, A).[21, 26]  However, the 
interpretation of this test can be difficult for some isolates resulting in false positive 
detection. [21, 25, 26]  More sophisticated techniques like PCR-based techniques are 
more specific and sensitive with a major advantage of shorter time to results but require 
technique knowledge, equipment, and are more costly. [21, 84]  Recently, in June 2010 
the CSLI lowered carbapenems breakpoints, to better detect KPCs without the need to 
perform the modified Hodge test. [85] Table 1.1 describes the old and the new 
breakpoints.   
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Table 2.1 Clinical and Laboratory Standards Institutes breakpoints for carbapenems and 
Enterobacteriaceae [80] 
 Older CLSI breakpoints 
(M100-S19) MIC(µg/mL) 
Revised CLSI breakpoints  
(M 100-S20) MIC (µg/mL) 
Agent S I R S I R 
Imipenem ≤4 8 ≥16 ≤1 2 ≥4 
Meropenem ≤4 8 ≥16 ≤1 2 ≥4 
Ertapenem ≤2 4 ≥8 ≤0.25 0.5 ≥1 
Doripenem …. …. …. ≤1 2 ≥4 
Susceptible = S, Intermediate = I, Resistant=R, Minimum inhibitory concentration= MIC 
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Figure 2.1 The modified Hodge test Mueller-Hinton agar plate. The MHT identified 
Isolate A as a positive KPC-producing isolate, while isolates B, C, and D were not KPC-
producers.  Adapted from Anderson et al. (2007). [25] 
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2.7 The role of hospital infection control  
 
In general, prior antibiotic use has been strongly implicated in the development of 
resistance. However, exposure to resistant bacteria from other sources, like other 
patients, healthcare personnel, or inanimate objects has also been associated with the 
emergence of resistant bacteria.[86]   
For gram-negative organisms, the impact of infection control measures seems to be 
less effective than antibiotic control measures when compared to gram positive 
organisms such as MRSA, thus the relative contribution of infection control in 
nosocomial gram-negative bacteria remains more controversial.[61]  However, enforced 
infection control measures were found to decrease the spread and the incidence of 
gram-negative bacteria like carbapenem-resistant Enterobacteriaceae (CRE) in many 
outbreaks. For example, an implementation of a comprehensive infection control 
intervention, composed of intensified infection control measures with routine rectal 
surveillance, was successful in reducing the incidence of CR-KP in an intensive care 
unit where strains producing the carbapenemase KPC were endemic.[87]  A quasi 
experiment found the use of active surveillance and contact precautions, as part of a 
multifactorial intervention, to be an effective strategy to decrease rates of nosocomial 
transmission of carbapenem-resistant K. pneumoniae colonization or infection.[88]  
Another quasi-experiment in a long-term acute care hospital showed the implementation 
of bundled interventions: daily 2% chlorhexidine gluconate baths for patients; enhanced 
environmental cleaning, surveillance cultures at admission; serial point prevalence 
surveillance (PPS); isolation precautions; and training of personnel resulted in 
preventing horizontal spread of KPC‐producing gram‐negative rods, despite ongoing 
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admission of patients colonized with KPC producers.[89]  However, there is a lack of 
information about antimicrobial restriction efforts and their influence on the incidence of 
CRE, but some researchers believe that antibiotic stewardship should focus on 
reduction of overall antibiotic use, not on limiting specific agents.[90] 
 
2.8 Confounding factors 
 
Confounding is an important concept in epidemiological studies; it occurs when a third 
variable(s) influence the relationship between an exposure or treatment and an 
outcome.[39]  This is considered problematic because the estimate of association 
between exposure and disease include the contribution of both the exposure and the 
confounder.  A confounding variable must be associated with the outcome variable; it is 
associated with the exposure but not caused by exposure. The presence of confounding 
can result in overestimation of the true association, underestimation of the true 
association, or change in the direction of the association between exposure and 
outcome.[39, 40]  Confounding by indication in particular, is the most common type of 
confounding in observational pharmacoepidemiological studies. It’s defined as a “type of 
selection bias in which the indication of a drug may influence the allocation of a patient 
into one or another of the comparison groups”.[91]  Controlling for a confounder variable 
in study design and/or data analysis is crucial to avoid confounding bias and to rule out 
its effect on the causal association between exposure (treatment) and the outcome of a 
pharmacoepidemiological study. 
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 Although antibiotic use is considered a major driver for development of antibiotic 
resistance, the nature of this relationship is complex.[16]  This is due to the presence of 
other confounding factors that may influence bacterial resistance in a hospital setting. 
Failure to deal with these confounders will make it difficult to evaluate and interpret the 
impact of antibiotic use on resistance. Some of these confounding factors are measured 
by an administrative database, and some are not measured.  A brief description of 
these confounding factors follows.  
One potential confounder is the use of antibiotics other than those studied. It is possible 
that more than an individual class of antibiotics use will aid in promoting resistance. The 
microbiological outcomes are carbapenem-resistant gram-negative bacteria which are 
often multidrug resistant. [50] The selection pressure imposed by the use of one 
antibiotic can result in the selection of bacteria resistant not only to that particular 
antibiotic but to other antibiotics, by co-resistance and cross resistance 
mechanisms.[50,51]  All broad spectrum antibiotic classes used to treat the bacteria of 
interest were included in the model selection and adjusting processes.  
Geographic location plays an important role in the distribution of many MDR gram-
negative bacteria, in particular CR-KPs, which are abundant in the Northeast areas, so 
elevated rates of resistant bacteria in certain hospitals could be due to their presence in 
certain geographical locations.[92]  Infection control efforts play a major role in bacterial 
resistance, poor infection control measures can result in the spread of antibiotic 
resistance.[15]  Also, for hospitals with a strict infection control policy, it is expected it 
will have lower rates of resistance transmission.  However, there is no quantitative 
measure of the quality and quantity of infection control in the hospital.  Additionally, 
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resistant organisms brought into the hospital and cross transmission may confound the 
relation between antibiotic use and resistance.  Patients infected with MDR bacteria 
transferred from another hospital may impact the resistance rate in that hospital.[24]  
However, this confounder cannot be adjusted for. 
Antimicrobial stewardship programs perform restriction policies for some formulary 
drugs, cover appropriate choice of empirical therapy, and assign proper dosage and 
duration of therapy. Proper implementation of stewardship would aid in lowering 
antibiotic resistance.[11, 12] Thus, it is expect for hospitals with a restriction policy to 
have lower rates of resistance.  Another potential confounder is the underlying severity 
of patient illness, as severely ill patients will presumably be at greater risk to develop 
resistance, because they have impaired host defenses and will receive more antibiotics 
compared to low risk patients.[17]  Finally, there are as in any research unknown 
confounder(s). 
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2.9 Previous Investigations 
2.9. 1 Carbapenem-resistant P. aeruginosa 
 
Several studies have been conducted to identify risk factors associated with CR-PA ; 
most of these investigations were single center case control studies as summarized in 
table 2.2. One single center case control study found no association between prior 
antibiotic use (including carbapenems) and acquisition of CR-PA in a multivariable 
model.[93] The authors considered antibiotic use at the time of study thereby ignoring 
earlier use of hospital antibiotics. Only admission frequency and presence of Foley 
catheters were identified as significant risk factors.  The authors believed that the 
observed high proportion of CR-PA in their institution was driven by a consequence of 
transmission of an organism already resident in their hospital rather than by selective 
antibiotic pressure.  Another investigation in two centers collected 253 isolates of CR-
PA between 2001 and 2006, found prior  carbapenem, fluoroquinolone, extended-
spectrum cephalosporin, and anti-anaerobic  agent use in the preceding 30 days of 
culture sampling to be significantly associated with CR-PA in univariate analysis.[23]  
However,  prior carbapenem use, transfer from outside facility, and duration of 
hospitalization prior to culture sampling were the only significant independent factors 
associated with CR-PA in the multivariable model. Also, ICU stay was used as a 
surrogate for severity of illness.  Another single center case control study found that 
exposure to carbapenems 15 days before isolation and receiving mechanical ventilation 
for more than 48 hours to be associated with MDR P. aeruginosa (defined as resistant 
to ceftazidime, ciprofloxacin, piperacillin, and imipenem) in a multiple logistic regression 
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analysis.[45]  Exposure to carbapenems within 14 days prior to isolation of positive 
cultures of CR-PA and renal failure were independently associated with CR-PA in 
multivariable analysis, in a single center case control study.[46] 
 The limitations of these case control studies investigating risk factors of CR-PA are the 
small sample size, single center institutions in which the stewardship and infection 
control practices may vary, impacting the generalizability of the results. The association 
between antibiotic use and resistance appears in many of the univariate analysis but 
when conducting a multivariable model many of these associations seem to fade. Some 
of these multivariable models adjusted for several confounders, but most relied on ICU 
stay as a measure of SOI rather than using other standard comorbidity-SOI indices. 
One ecological single center study investigated the correlation between antimicrobial 
use density (AUD), which they used as a surrogate for defined daily dose /1000 patient-
days-of carbapenem and carbapenem-susceptible P. aeruginosa in patients when  
followed every six months for the period between 2006 and 2008. They found a 
significant negative correlation between meropenem susceptibility in P. aeruginosa and 
total AUD of meropenem and doripenem. It wasn’t clear how they adjusted for the 
dependency between their observations and how the correlation analysis was 
conducted.[94] 
One retrospective, longitudinal study conducted was a time series analysis with months 
as a unit of analysis over the period 2001-2005 that evaluated the association between 
carbapenem use (defined daily dose) and CR-PA incidence rates and proportions in a 
single hospital. In their multivariate analysis, the use of group 2 carbapenems 
26 
 
(imipenem, meropenem, and doripenem) was highly associated with CR-PA 
proportions. However, ertapenem use was not associated with CR-PA.[95] 
Finally, a multicenter study (25 hospitals) investigated the role of ertapenem use on CR-
PA at an aggregate level and found no significant association between change in 
ertapenem use, carbapenem use, fluoroquinolone use and CR-PA. [47] They only 
adjusted for other antipseudomonal antibiotics in their model. 
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Table 2.2 Carbapenem-resistant P. aeruginosa previous studies 
Author Study design Setting(s) Risk factors 
Eagye et al., 
2009 
Case-control Single 
center 
Admission frequency, Foley 
catheters 
Lautenbach et 
al., 2010 
Case-control Two 
centers 
Carbapenem use, transfer from 
outside facility, duration of 
hospitalization 
Cao et al., 2004 Case-control Single 
center 
Carbapenem use, mechanical 
ventilation 
Zavascki et al., 
2005 
Case-control Single 
center 
Carbapenem use, renal failure 
Carmeli et al., 
2011 
Ecological, 
longitudinal study 
Single 
center 
Carbapenem use 
Eagye et al., 
2010 
Ecological, 
longitudinal study 
Multicenter None 
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2.9.2 Carbapenem-resistant K. pneumoniae 
 
CRE was rare until 2006; however, the incidence has been increasing since then, with 
outbreaks reported in the northeastern United States and spread of CRE described in 
other countries over the world.[90]  Summary of the studies that investigated CR-KP are 
displayed in table 2.3. 
One case control study where cases were patients with KPC-producing K. pneumoniae 
compared with control subjects with carbapenem-susceptible K. pneumoniae was 
conducted in two medical centers.  In the multivariable analysis, only APR-DRG 
extreme illness category, prior fluoroquinolone use, and prior extended spectrum 
cephalosporin use were significantly associated with isolation of KPC-producing K. 
pneumoniae. [42] Prior antibiotic exposure was defined as at least two days of therapy 
administered during the 30 days prior to the culture. The authors mentioned that a very 
few patients had a history of carbapenem use (1.1%).  As such, prior use of 
carbapenems as a risk factor for KPC production in K. pneumoniae isolates cannot be 
excluded. 
In a single center case control study, patient conditions like malignancy, neurologic 
disease, poor functional status, high Charlson comorbidity index score, presence of 
central venous line, Foley catheters, mechanical ventilation, and ICU stay were 
associated with carbapenem-resistant K. pneumoniae in univariate analysis.[29] In 
addition, cases were shown to have received more antibiotics than controls. However, 
the multivariable model identified prior use of fluoroquinolones to be the only antibiotic 
independent predictor of carbapenem-resistant K. pneumoniae isolation along with poor 
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functional status and ICU stay. Carbapenem use could not be included in the model as 
none of the controls received carbapenems.  
Another matched case control study in two health centers compared carbapenem –
resistant K. pneumoniae to carbapenem-susceptible K. pneumoniae. The following were 
identified as predictors of CR-KP in univariate analysis: history of Chronic Obstructive 
Pulmonary Disease (COPD); admission to the ICU; mechanical ventilation; prior use of 
antipseudomonas penicillin; fluoroquinolones; glycopeptides; carbapenems; presence of 
tracheotomy; and having surgery with the use of a foreign body.[43]  Prior antibiotic use 
was identified as an exposure that occurred only during the hospitalization in which the 
infection developed and the antibiotic had been administered for at least 3 consecutive 
days prior to the development of the infection.  The multivariable analysis for matched 
data showed that prior use of fluoroquinolones and antipseudomonal penicillins were 
independent risk factors for CR-KP infections.  Another matched case control study 
identified 99 cases of CR-KP and 99 control with carbapenem-susceptible K. 
pneumoniae.[22]  In the univariate analysis, transplant recipient, mechanical ventilation, 
ICU stay, length of stay before infection, prior use of cephalosporin, beta-lactam and/or 
beta-lactamase inhibitor, carbapenem, and aminoglycosides were associated with CR-
KP. The multivariable model had shown prior exposure to cephalosporins, 
carbapenems, and longer length of stay before infection to be significantly associated 
with CR-KP acquisition.  Antibiotic exposure was identified during patient hospitalization 
or within 3 months before the diagnosis of K. pneumoniae infection.   
Finally, a case control study design found that ICU admission within two weeks, tracheal 
intubation, mechanical ventilation, exposure to carbapenems, fourth generation 
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cephalosporins, piperacillin-tazobactam, and glycopeptides to be associated with the 
isolation of CR-KP in univariate analysis.[44] The multivariable model found only ICU 
admission, prior exposure to carbapenems, and glycopeptides to be independently 
associated with CR-KP isolation.  However, the sample size was relatively small, and 
resistance mechanisms were not identified. 
To summarize, prior use of carbapenems, fluoroquinolones, and extended- spectrum 
cephalosporins are associated with isolation of carbapenem resistant CR-KP as 
identified in several case control studies. Most of the studies had a small sample size 
and were single centered which limit their generalizability, especially as infection control 
measures vary among these institutions.   
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Table 2.3 Carbapenem-resistant K. pneumoniae summary studies 
Author Study design Setting(s) Risk factors 
Gasink et al., 2009 Case-control Two centers APR-DRG extreme 
category, 
fluoroquinolones, 
extended-spectrum 
cephalosporins 
Schwaber et al., 
2008 
Case-control Single center Fluoroquinolones, 
poor functional 
status, ICU stay  
 
Falagas et al., 2007 Case-control Two centers Fluoroquinolones, 
antipseudomonal 
penicillins  
 
Patel et al., 2008 Case-control Single center Carbapenems, 
cephalosporins, 
length of hospital 
stay  
 
Wu et al., 2011 Case-control Single center ICU admission, 
carbapenems, 
glycopeptides  
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CHAPTER 3 
METHODS 
3.1 Study design 
 
This was an ecological longitudinal observational study of hospitals within the University 
Health System Consortium (UHC) database. The outcomes of interest were 
carbapenem- resistant Pseudomonas aeruginosa (CR-PA) and carbapenem-resistant 
Klebsiella pneumoniae (CR-KP). The exposures of interests included hospitals’ 
antibacterial drug use, case mix index (CMI), aggregated 3M All Patient Refined 
Diagnosis Related Group (APR-DRG) Classification System, and hospital 
demographics (bed size and geographical location). 
3.2 Data source 
 
The UHC is a national alliance of 103 academic medical centers and 206 of their 
affiliated hospitals representing approximately 90% of the nation's non-profit academic 
medical centers. The UHC provides a mechanism for collaboration for research across 
academic medical centers, which are geographically distributed throughout the U.S. A 
subset of UHC hospitals participate in the Clinical Resource Manager (CRM) Database 
and will serve as the data source. It contains Uniform Billing (UB-92) data, inpatient 
medication use from charge transaction masters, and billing files from participating UHC 
members. Patient records contain detailed information on inpatient care, and this 
includes primary and secondary diagnoses (in International Classification of Diseases, 
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9th Revision, Clinical Modification [ICD-9-CM] format), inpatient procedure codes (in 
ICD-9-CM format), patient demographic information (age, race, and gender), and 
hospital demographic information (bed size and geographical location). [96] The 
database also contains admission and discharge dates as well as information on 
comorbidities, severity of illness, physician specialty, length of stay (LOS), costs, and 
clinical outcomes such as inpatient mortality and complications rates.  Antibacterial drug 
use was used from this database; the validation of UHC database and its assessment of 
hospital antibacterial drug use have been described. [48] 
3.3 Antibacterial drug Use 
  
The UHC database provides antibiotic use data that are based on charges for patients 
not the overall amounts the institution purchases.  Antibacterial agents whose use has 
been reported as risk factors for the development of CR-Pa and CR-KP as identified in 
the literature review are listed in table 3.1. The systemic use of these antibiotics in adult 
(>=18) inpatients discharged between January 1, 2006 and December 31, 2009 was 
obtained from billing records and reported as days of therapy per 1000 patient days 
(DOT/1000 PDs).  Any single dose of antibiotics that was received by a patient was 
reported as one DOT regardless of multiple dose administration.  For example, 
administration of gentamicin every 8 hours for 3 doses, or administration of the entire 
daily dose every 24 hours, would be counted as one DOT. The defined daily dose 
(DDD) method of reporting drug use is adopted by World Health Organization (WHO), 
but important deficiencies were presented when compared to DOT method.[97]  In 
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addition, CMI, geographic location, proportion of patients in each of the four APR-DRG 
categories, and bed size for each hospital were obtained for the study period. 
Table 3.1 Systemic use of antibacterial drugs categorized into groups 
Antibacterial Group Antibacterial agents 
Carbapenems Imipenem, meropenem, ertapenem, 
doripenem  
 
Fluoroquinolones Ciprofloxacin, levofloxacin, moxifloxcacin,  
gatifloxacin  
 
Third-and fourth-generation  
cephalosporins, monobactams 
 
Ceftriaxone, cefotaxime, ceftazidime, 
cefepime, aztreonam 
 
Aminoglycosides 
 
Gentamicin sulfate, tobramycin, amikacin 
Antipseudomonal  Penicillins Piperacillin-tazobactam, ticarcillin-
clavulanate 
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3.4 Severity of illness  
 
 Measuring severity of illness using aggregate level data is not a well established 
concept. Overall hospital CMI [the average of DRG weights for all of an individual 
hospital’s DRG-paid Medicaid claims] had been considered an indicator of the intensity 
of hospital resource utilization and can be used to compare hospital performance, but it 
is less sensitive to the severity of illness from a clinical perspective. [98, 99]  In addition 
to CMI, another severity of illness measure based on the APR-DRG classification 
system was used in this present investigation; this measure reflects the clinical 
complexity of a patient population. The underlying clinical principle of the APR-DRGs is 
that the severity of illness and risk of mortality of a patient depends to a great extent on 
the patient’s underlying characteristics. This system assesses the relative severity of a 
patient’s illness based on the severity level of the secondary diagnoses and interactions 
between secondary diagnoses, age, principal diagnosis, and certain procedures. There 
are four subclasses of SOI (minor, moderate, major, extreme) based on the presenting 
DRG.[100, 101]  The UHC database includes the number of patients within each of the 
four categories for each participating hospital for each year. Hence, the proportions of 
patients within each category for each year were calculated.  The APR-DRG proportions 
and CMI were highly correlated, especially the extreme category of the APR-DRG.  
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 3.5 Antimicrobial susceptibility  
 
“Whole house” antibiograms from all hospitals for which antibacterial drug use data 
were obtained were requested from 2006 through 2009. An email request was sent to 
50 hospitals accompanied by an online survey for which antibiotic use data from 2006 to 
2009 were obtained.  Only antibiograms with a full calendar year of susceptibility data 
from all clinical sources, at least 30 isolates for each organism and those including total 
number of isolates and proportion of susceptible isolates were included in the final 
dataset. The desired outcomes, carbapenem (imipenem or meropenem)-resistant P. 
aeruginosa and K. pneumoniae were calculated from theses antibiograms. Both 
proportions and rates of resistance for CR-Pa and CR-KP were recorded.  The resistant 
proportion was the number of resistant isolates divided by the total number of isolates, 
and the resistant incidence rate was the number of resistant isolates per 1000 adult 
patient discharges, and per 1000 adult patient days (PDs). The number of adult 
discharges and adult patient days were obtained from the UHC database.  
3.6 Survey 
 
Hospitals that participated in the UHC-CRM for which the antibacterial use data were 
obtained from 2006 to 2009 were invited to complete a survey in January 2011 (with 
follow-up requests to non-responders in April 2011 and August 2011). The online survey 
was sent to each of the 50 hospitals along with the request for new antibiograms.  Each 
hospital contact, usually clinical pharmacy infectious disease specialists but may also 
include infectious disease physicians, clinical microbiologists, or infection control 
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practitioners, received an online survey by REDCap (Research electronic data capture) 
to obtain data that are not available to us through UHC. REDCap is a secure, web-
based application designed to support data capture for research studies, providing: 1) 
an intuitive interface for validated data entry; 2) audit trails for tracking data 
manipulation and export procedures; 3) automated export procedures for seamless data 
downloads to common statistical packages; and 4) procedures for importing data from 
external sources.[102]  The online survey was divided into three parts. The first part 
requested additional information regarding susceptibility testing methods and 
antibiograms construction, including the inclusion/exclusion of duplicate isolates, 
method(s) of routine susceptibility testing, policy regarding surveillance cultures and 
intermediate susceptible isolates. The second part requested information about 
carbapenem-resistant Enterobacteriaceae and carbapenem-resistant K. pneumoniae 
including hospital encounter of such organisms in the past five years, rate of isolation in 
the past year, source (e.g. transfer from another hospital and/or nursing home), and 
microbiological technique used to identify and/or confirm CRE.  In order to compare the 
number of isolates of carbapenem-resistant K. pneumoniae obtained from hospital 
antibiograms to the number of resistant isolates obtained from the clinical microbiology 
laboratory in each hospital a question about the reflection of the rate of isolation of 
these bacteria in hospitals antibiograms was included in the survey. The third 
component was about antimicrobial stewardship programs (ASP), specifically about the 
role of ASP in managing CR-KP cases, isolation procedures and measures with such 
cases, and restriction policies for carbapenems. It was also asked if there had been any 
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changes in the ASP policies over the current study period. The survey is provided in 
appendix A.   
 
3.7 Data collection 
 
Each hospital was offered $100 per year of antibiograms and for the completion of the 
online survey. Antibiotic use data, CMI, APR-DRG and other demographics were 
available for 50 hospitals for the period of 2006-2009. The antibiograms/survey requests 
were sent to all contacts of the 50 hospitals in the period of January 2011, a second 
round of requests was sent to non-responders by April 2011, and a final round of 
reminders was sent by August 2011. Of the total 50 hospitals approached, 40 hospitals 
provided antibiograms, thirty of which completed the online survey. The outcome data, 
proportions and rates of CR-PA and CR-KP were calculated directly from the 
antibiograms. The UHC obtained variables are listed in table 3.2. 
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Table 3.2 Description of the analysis variables obtained by UHC 
UHC data variable Unit Symbol used SAS 
code 
Fluoroquinolones 
Fluoroquinolones (except moxifloxcacin) 
 
DOT/1000 PDs FQ 
FQMo 
Carbapenems 
Carbapenems (except ertapenem) 
DOT/1000 PDs CB 
CBE 
Aminoglycosides DOT/1000 PDs AG 
3rd& 4th  generation cephalosporins 
Antipseudomonal cephalosporins 
DOT/1000 PDs  CEPHt 
CEPHn 
Piperacillin-tazobactam, ticarcillin-clavulanate DOT/1000 PDs ExPen 
Hospital bed size Number of 
beds 
Bedsize 
Hospital geographic location Name  
Mid-Western 
Mid-Continent 
Southeastern 
Location 
1 
2 
3 
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Mid-Atlantic 
Western 
New-England 
 
4 
5 
6 
Hospital CMI No unite CMI 
Proportion of patients with APR-DRG score  
minor 
Proportion  minor 
Proportion of patients with APR-DRG score  
moderate 
Proportion moderate 
Proportion of patients with APR-DRG score  
major 
Proportion major 
Proportion of patients with APR-DRG score  
extreme 
Proportion extreme 
Carbapenem restriction Yes/ No restriction 
Removal of duplicate isolates Yes/No dup 
Including surveillance cultures Yes/No surv 
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3.8 Modeling longitudinal (repeated measures) data 
 
Longitudinal data  
This analysis involves longitudinal measures of bacterial resistance and antibiotic use 
over a four-year period. In this set of longitudinal data (repeated measures), the 
assumptions of independence between any two observations from different hospitals 
are valid, as this sample represents a random sample of UHC hospitals. In contrast, any 
two observations from the same hospital are correlated as they will have the same basic 
characteristics and accordingly they will not be independent.[103]  Modeling correlated 
data as if they were independent can result in incorrect inferences of the regression 
parameters due to underestimation of standard errors and insufficient 
estimators.[103,104]  Therefore, there are specific statistical methods to model 
longitudinal data. 
Mixed models, generalized mixed models, and generalized estimating equations are all 
methods used to analyze longitudinal data and will be explained in this section. All of 
these methods share one common feature, which is the predetermination of the 
covariance structure to account for correlation between observations. [105,106] Table 
3.3 compares these methods and their use in SAS. 
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Table 3.3 Comparison of most common statistical methods to analyze longitudinal data 
Model Output 
variables 
Types of 
inputs, 
effects 
Assumptions Method  to 
estimate 
parameters 
Goodness 
of fit 
criteria 
Missing 
data 
LMM Interval Categorical, 
interval, 
random 
effects 
Normality Need to be 
specified in 
the model 
AIC, 
AICu, BIC 
MAR 
GEE Categorical, 
interval 
Categorical, 
interval, 
combine fix 
and random 
effects 
Exponential 
family 
Need to be 
specified in 
the model 
QIC , 
QICu 
MCAR 
GLMM Categorical, 
interval 
Categorical, 
interval, 
random 
effects 
Exponential 
family 
Need to be 
specified in 
the model 
Pseudo-
AIC 
Pseudo-
BIC 
MAR 
Note: Linear mixed models (MM), Generalized estimating equations (GEE), Generalized 
Linear mixed models (GLMM), Akaike’s information criterion (AIC), Schwarz’s Bayesian 
information criterion (BIC), pseudo-Akaike’s information criterion (pseudo-AIC), pseudo-
Schwarz’s Bayesian information criterion (pseudo-BIC), quasi-likelihood under the 
independence model criterion (QIC), missing at random (MAR), missing completely at 
random (MCAR). 
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The following section will provide an overview of each of these statistical methods. 
 
 Linear Mixed models (LMM) 
These models contain both fixed and random effects and perform analysis by way of 
structured covariance models. The LMM procedure estimates parameters by restricted 
maximum likelihood (REML) technique which was introduced by Patterson and 
Thompson (1971). The restricted likelihood is maximized under the assumption of 
normal distribution of the data. All available data can be used with LMM as long as any 
missing data are missing at random (MAR).[107,108]  Covariance parameters are 
estimated by the method of moments though solving expressions for expected mean 
squares.[107,108]  Model fit criteria usually involves Akaike’s information criterion (AIC) 
and Schwarz’s Bayesian information criterion (BIC). Both can be used in the model 
selection process. [107-109] 
 
The notation for linear mixed models is: 
y X Z e     
 
 Where y , X ,  and e are as defined in the fixed effects model, and 
( 1,  2,  . . .,  )q      random effect/coefficient parameters. The Z is a second design 
matrix with dimension n×q  giving the values of random effects corresponding to each 
observation.[108] 
A covariance structure must be explicitly specified to account for within-subject 
correlation by specifying how observations within a subject or cluster are correlated with 
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each other.  Misspecification of the covariance structure can yield to invalid results.[107-
110]  Examples of most commonly used correlation matrices are described in table 3.4 
 
Generalized linear mixed models (GLMM) 
The GLMM is an extension of the family of generalized linear models (GLM).  These 
models have the ability to account for within-subject correlations by explicitly specifying 
a working correlation matrix and are considered subject-specific models.[108,111]  The 
GLMM inflates GLMs by including some variables as random effects. It allows the within 
subjects dependence to differ from one subject to another by means of the random 
variation of the linear combination of covariates and the residual variation. The random 
variation can be expressed in the random intercept and random slope. [108,111,112]  
The change of an individual’s response can be evaluated by including these random 
effects in the model; consequently they are considered to be subject-specific models. 
Similar to linear mixed models, GLMM handles missing data if they were missing at 
random. Thus, for missing data, the working correlation from data containing missing 
values can be estimated by using all the available pairs of data. Moreover, generalized 
mixed models by include variables of non-normal distribution, in particular when the 
response variable has a distribution from one of the exponential family of distributions. 
For example, binary, binomial, Poisson, negative binomial, normal, beta, gamma and 
inverse Gaussian distributions are all members of the exponential family.[108,111, 112] 
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The notation for GLMM is: 
  
                   ( ) X Z   eg       
Where  is the vector of expected means of the observations and is linked to the model 
parameters by a link function, g , X , and Z  are the fixed and random effects design 
matrices. Moreover,  is the vector of fixed parameters and  is the vector of random 
effects parameters.[108] 
 
The GLMM implements the estimation technique using residual pseudo-likelihood and 
was proposed by Wolfinger and O’Connell (1993) with a subject specific 
expansion.[112-114]  This method is referred to as ‘pseudo-likelihood’ because the 
likelihood function maximization is based on the pseudo variable (pseudo data) and not 
that of the original data. Consequently, model fitting criteria such as pseudo-AIC and 
pseudo-BIC are not comparable to the log-likelihood criteria used in mixed models and 
should be interpreted cautiously.[108,112-114]  In order to fit GLMM models, an 
appropriate distribution, link function, and working correlation structure should be 
specified.   
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The Generalized Estimating Equations (GEE) 
 
The GEE method was introduced by Liang and Zeger 1986 for analyzing correlated 
response variables in longitudinal data. The GEE model extended generalized linear 
models by assuming a known function of the marginal expectation of the outcome 
variables by using the quasi-likelihood approach.[115]  The GEE model accounts for 
within-subject correlations by explicitly specifying a working correlation matrix for 
different types of response data, in particular the exponential family of 
distributions.[115,116]  Also, the GEE method handles missing data as if they were 
missing completely at random (MCAR). [115,116] 
The notation for GEE is: 
  
1
1
S( ) D V (Y ( )) 0
K
i i i i
i
  

        
Where 
 D ii





 
Since 
 g( ) xij ij   
where g is the link function, the p n  matrix of partial derivatives of the mean with 
respect to the regression parameters   for the thi  subject.[115,117] 
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The GEE model is also known as a “marginal” model as it models a known function of 
the marginal expectation of the response variable as a linear function of the explanatory 
variables.[116,118]  The effect of the between-subjects factor is modeled separately 
from the within-subjects correlation. Thus, the interpretation of the parameters does not 
depend on a particular subject, but rather it is valid for the whole population of possible 
subjects in the study.  Accordingly, these parameters can be referred to as population-
averaged parameters.[115,116,118]  Regression coefficients of such model describe 
the average population response curve. One unique advantage with GEE models is the 
robust covariance matrix concept proposed by Liang and Zeger (1986) which entails 
that as long as the mean model is correct, the parameter estimates are consistent as 
the number of subjects (hospitals) becomes large.[115,116,119,120]  This is of 
considerable importance in cases of correlation structure misspecification where one 
can still obtain consistent parameters estimates.  The quasi-likelihood under the 
independence model criterion (QIC) proposed by Pan (2001) is an extension of the AIC 
and can be used in model fit assessment.[121,122] 
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Table 3.4 Commonly used correlation matrices with correlated observations [105,110] 
Correlation structure Definition 
Independence Each observation in a subject is completely uncorrelated 
with every other observation in that subject 
Exchangeable 
(Compound 
Symmetry) 
Each observation within a subject is equally correlated with 
every other observation in that subject 
Autoregressive For two observations taken close in time within a subject, 
they will be more closely correlated than two observations 
taken far apart for the same individual. 
Unstructured No assumption is made about the magnitude of correlation 
between any two pairs of observation.  
 
 
 
 
 
 
49 
 
 
3.9 Statistical analysis 
3.9.1 Software 
 
Statistical analyses were performed using SAS (version 9.2; SAS Institute, Cary, NC) 
and JMP (version 8.0; SAS Institute, Cary, NC).  JMP was mainly used for descriptive 
statistics while SAS was used for the GEE analysis.  All tests were two-tailed; a p-value 
< 0.05 was considered significant. 
 
3.9.2 Summary statistics 
 
Descriptive statistics including the mean, standard deviation, and full range were 
calculated for antibiotic use groups. The median, interquartile range, and full range were 
calculated for CR-KP rates and proportions and the mean, standard deviation, and full 
range were calculated for CR-PA rates and proportions.   
Mixed model ANOVA method was used to report trends in antibiotic use and resistance 
rates and proportions of CR-PA and CR-KP over the study period. The mean use of 
carbapenem use and rates of CR-PA were compared among hospitals that did vs. did 
not restrict carbapenem agents using the Wilcoxon Rank-Sum Test.  
 
3.9.3 Modeling carbapenem-resistance gram-negative bacteria 
 
The analytical approach used in this investigation was generalized estimating 
equations. The QIC value was used to determine the best distribution and link functions, 
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as well as working correlation structure. [121,122]   For the CR-PA rates (1000 PDs), a 
normal distribution, identity link, and first-order autoregressive working correlation 
structure were selected after comparing QIC values (the smaller the better).  CR-PA 
proportions are considered limited range variables; they are limited between 0 and 1. 
Falsely assuming normality in such cases can lead to incorrect results.[119]  Hence, a 
binomial distribution, logit identity, and first-order autoregressive working correlation 
structure were selected for CR-PA proportions. 
Given that almost half of the CR-KP data were of zero value, using proportion or 
incidence rate was not feasible. Therefore, CR-KP data were treated as a binary 
outcome (present vs. absent). First, a cut point of a proportion ≤ 1% was considered an 
“absence” response and >1%  was considered a “present” response, however, only 
24% of the observations were “present” outcome and this resulted in some 
convergence/ iteration issues in running the model through SAS. Thus, the raw number 
of isolates was used to generate a binary categorical variable as follows: if a hospital 
(according to its antibiogram) encountered less than 5 isolates per year then it was 
considered as an “absent” response, if the hospital encountered 5 or more isolates per 
year then it was considered as a “present”.  Consequently, 41% of observations had the 
outcome “present”. Binary distribution, logit link, and 1st order autoregressive working 
correlation structure were chosen for CR-KP. 
Each of the three outcomes was analyzed separately. Variables were added to the 
model based on their importance according to previous findings in literature and 
preliminary analysis of the data.  For CR-PA rates and proportions the following 
explanatory variables were included in the model selection process: fluoroquinolones 
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(ciprofloxacin, levofloxacin, gatifloxacin); carbapenems (imipenem, meropenem, 
doripenem); antipseudomonal penicillins (piperacillin-tazobactam, ticarcillin-
clavulanate); antipseudomonal cephalosporins (ceftazidime, cefepime, aztreonam); 
aminoglycosides (gentamicin, tobramycin, amikacin); and hospital CMI, patient-
proportion within the APR-DRG categories. The patient-proportions within the APR-
DRG categories were not combined with CMI.  Variables were entered and models 
were compared using QICᵤ. QICᵤ is a simplified version of QIC that can be used to 
select the most parsimonious model, that is, the best model is the one with smallest 
QICᵤ.[122]  A Huber-White sandwich estimator (robust estimator) was used as a way to 
ensure that the variances were robust. Specifically, robust variances are important as 
they provide accurate assessments of the sample-to-sample variability of the parameter 
estimates even if the model is misspecified.[115,116,118]  After selection of the “best 
model”, adjusting for potential confounders was performed.  Each of the confounding 
variables (hospital bed size, geographical location, and variables that were not included 
in the “best” model, e.g. CMI, other antibiotic classes) were added to the model to 
assess their impact on parameter estimates.  A confounding variable that changed 
parameter estimates by ≥ 20% was added to the selected model.[123]  For the test of 
model effects, Type III, was selected for all analysis as it does not depend on the entry 
order of the variables like Type I does. Test Type III is typically preferred unless the 
order of the variables is necessary.[117] 
For CR-KP dependent variable,  the following explanatory variables were included in the 
model selection process: fluoroquinolones (ciprofloxacin, levofloxacin, gatifloxacin, 
moxifloxcacin); carbapenems (imipenem, meropenem, doripenem, ertapenem); 
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antipseudomonal penicillins (piperacillin-tazobactam, ticarcillin-clavulanate); third-and 
fourth-generation cephalosporins (ceftazidime, cefepime, aztreonam, ceftriaxone, 
cefotaxime); aminoglycosides (gentamicin, tobramycin, amikacin);  hospital CMI;  
patient-proportion within the APR-DRG categories; and geographical location. 
After selecting the model; the adjustment for potential confounders was performed in a 
similar fashion to the CR-PA modeling process.  
3.10 Human subjects’ protection and data privacy 
  
VCU IRB exemption was obtained for this study. A dataset was constructed from the 
University Health System Consortium (UHC) data warehouse.  Access to the dataset 
was restricted to those individuals listed on the study protocol, and the dataset was 
centrally maintained in a password-protected environment.  Disclosure of any kind of 
information did not take place without the expressed written permission of UHC or as 
required by law. Results will be published in such a way that no hospital will be 
individually identifiable. Data within UHC‟s Clinical Resource Manager is compliant with 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA). This study 
qualified for exemption according to 45 CFR 46.101(b) Category 4 at Virginia 56  
Commonwealth University internal review board VCU IRB#: 12377. A copy of the IRB 
Approval form can be found in the Appendix B. 
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CHAPTER 4 
Results 
 
4.1 Descriptive statistics of hospitals 
 
Forty hospitals were included in the analysis of this project out of the 50 hospitals 
approached. Six of the total 50 hospitals did not provide any antibiograms nor did they 
respond to the survey. One hospital responded to the survey but did not provide any 
antibiograms. Three hospitals provided antibiograms that cannot be used; two of them 
did not include carbapenem susceptibility results and one antibiogram did not include 
the total number of isolates for organisms of interest.  
The 40 participating hospitals were located in different geographical locations across 
the continental U.S. Eight of the participating hospitals were located in the Mid-Western 
region, eight hospitals were located in the Mid-Continent region, ten hospitals were 
located in the Mid-Atlantic region, both the South-Western and Western regions had six 
hospitals in each, and two hospitals were located in the New-England region. Table 4.1 
lists patient and hospital demographics for 2009 at 40 UHC hospitals.  
The observations in the study period represent a total of 22,224,512 total patient days 
and 3,960,380 discharges. During this period, 2,022,956 patients received antibiotics. 
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Table 4.1 Characteristics of 40 member hospitals of the UHC in 2009 
Characteristics  Mean (SD) Range 
Adult patient age 52 ± 4 44 - 59 
Bed size 558 ±190 216 - 1156 
Case mix index 1.67 ± 0.16 1.21 – 1.99 
Mean length of stay, days 5.59 ± 0.45 4.74 – 6.79 
Total Patient Discharges 25283 ± 8615 11594 - 54192 
Total Patient Days 141509 ± 48733 59763 - 282327 
Surgical procedures per 
1000 discharges  
356 ± 56 194 - 502 
Diagnosis per 1000 discharges  
Urinary Tract infections 86 ± 15 49 - 119 
Pneumonias 62 ± 12 40 - 94 
Blood stream infections 54 ± 11 31-  88 
Bone marrow transplants 3.5 ± 3.2 0 - 15 
Solid organ transplants 10.4 ± 6.3 0 - 29 
 one hospital was excluded for these characteristics  
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4.2 Summary statistics of antibiotic use 
 
Antibiotics use data were available for all 40 hospitals over the study period. Each 
antimicrobial group was assessed for trends over the study period. The mean (± SD) of 
antibiotics under this investigation are presented in table 4.2 and figure 4.1. One 
hospital’s antibiotic use data for 2009 was excluded because the data for that year were 
not correct. For antipseudomonal penicillins, piperacillin-tazobactam was mainly used in 
most hospitals. Total use of five broad spectrum antibiotic classes increased 
significantly over the study period, from 354.0 (± 72.2) DOT/1000 PDs in 2006, to 369.7 
(± 80.3) DOT/1000 PDs in 2009 (P=.0206). This increase is driven primarily by an 
increase in carbapenem and piperacillin-tazobactam use. Total carbapenem use 
increased by 24% over the study period, from 36.1(± 21.7) DOT/1000 PDs in 2006, to 
44.8 (±24.4) DOT/1000 PDs in 2009, (P <.0001). A similar increase of 25% was 
observed with piperacillin-tazobactam use 73.8 (±39.6) DOT/1000 PDs in 2006 to 92.3 
(±37.2) DOT/ 1000 PDs in 2009 (P <.0001). On the other hand, total fluoroquinolone 
use decreased by 8% over the study period; from 130.0 (± 40.6) DOT/1000 PDs in 
2006, to 119.6 (± 36.9) DOT/ 1000 PDs in 2009 (P= 0.0013). Total aminoglycoside use 
decreased by 18% over the period of this investigation, from 28.3 (± 9.5) DOT/1000 
PDs in 2006, to 23.1 (± 8.7) DOT/1000 PDs in 2009 (P<0.0001). Total third-and fourth-
generation cephalosporin use did not change significantly over the study period. It is 
worth mentioning that fluoroquinolone use represented the highest proportion of broad 
spectrum antibiotics. For example, in 2009 fluoroquinolone use was 32%, followed by 
piperacillin-tazobactam 25%, total third-and fourth-generation cephalosporins 25%, 
carbapenem use was 12%, and finally aminoglycosides use was 6% of total use. 
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Table 4.2 Changes in antibacterial drug use among 5 classes of broad spectrum 
antibiotics from 2006 -2009 
Antibiotic Year Mean use 
(DOT/1000PDs)  
SD Range 
Carbapenems 2006 35.92 21.71 7.00-  98.8 
 2007 38.96 21.78 11.32 -98.54 
 2008 42.19 24.8 10.80 – 
121.72 
 2009 44.80 24.38 8.51 – 
160.56 
Fluoroquinolones 2006 130.01 40.55 52.93 – 
212.53 
 2007 129.85 37.89 51.19 – 
217.70 
 2008 124.96 39.71 44.01 – 
219.31 
 2009 119.62 36.87 41.73 – 
200.63 
Third-and fourth-generation 
cephalosporins 
2006 87.44 35.50 24.97 – 
226.37 
 2007 89.84 34.87 27.80 – 
228.55 
 2008 89.77 33.14 26.09 – 
217.43 
 2009 92.24 37.47 23.37 – 
253.17 
Aminoglycosides 2006 28.33 9.53 16.25- 61.85 
 2007 27.49 9.04 14.85 – 
58.11 
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 2008 25.34 8.72 12.10 – 
53.54 
 2009 23.05 8.65 10.11 – 
46.17 
Antipseudomonal penicillins  2006 76.69 37.30 1.66 – 
175.75 
 2007 81.83 37.53 1.91 – 
155.88 
 2008 89.13 36.54 3.05 – 
149.15 
 2009 93.53 38.69 3.67 – 
161.31 
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Figure 4.1 Changes in antibacterial drug use and carbapenem-resistant P. aeruginosa 
over 4 years 
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4.3 Summary statistics of resistance 
 
Antibiograms were available for 40 hospitals. Of the total 160 possible hospital years, 
antibiograms that met the criteria (identified in methods chapter, section 3.5) were 
available for 146 (91.25%).   Four years of antibiograms from 30 hospitals, three years 
of data from eight hospitals, and two years of data from 2 hospitals were obtained. CR-
PA and CR-KP rates and proportions are summarized in tables 4.3 and 4.4 respectively.  
4.3.1 Carbapenem-resistant P. aeruginosa 
The mean, standard deviation, and range calculated values are presented in table 4.3.  
The mean proportion and  incidence rate for carbapenem-resistant Pseudomonas 
aeruginosa (per 1000 patient days and discharges) did not change significantly  over 
the study period (P = 0.30, 0.17, 0.12; respectively, figure 4.3).   
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Table 4.3 Changes in carbapenem susceptibility among P. aeruginosa  
Bacteria-resistance measure Year Mean SD Range 
CR-PA proportion (%) 2006 20 6.9 7 - 37 
 2007 20 7.7 6 - 36 
 2008 19 7.7 5 - 36 
 2009 19 5.7 6 - 30 
CR-PA rate (1000 PDs) 2006 1.02 0.65 0.10  – 2.65 
 2007 1.00 0.72 0.20- 2.80 
 2008 0.91 0.72 0.15 – 2.66 
 2009 0.88 0.57 0.19 – 2.12 
CR-PA rate (1000 discharges) 2006 5.73 3.87 0.42– 15.02 
 2007 5.67 4.30 1.18 – 16.30 
 2008 5.31 4.61 0.83 – 18.78 
 2009 4.93 3.43 1.09 – 12.89 
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4.3.2 Carbapenem-resistant K. pneumoniae 
 
The median, interquartile range and total range were calculated for each of the four 
years and are presented in table 4.4. Microbiology results obtained from antibiograms 
for CR-KP varied among hospitals and the years of this study.  Almost one half of the 
participating hospitals (22 hospitals) reported 0.5 to 2 percent carbapenem-resistant K. 
pneumoniae in at least one year of the study period. Nine hospitals reported a zero 
percent of CR-KP for all years, while 4 hospital hospitals reported a CR-KP percent that 
is more than 2 and less than 10 in at least one year of the study period. Twenty seven 
hospitals had zero percent/rate of CR-KP as reported in their antibiograms; this number 
decreased over the study period as follows:  22 hospitals in 2006, 20 hospitals in 2007; 
17 hospitals in 2008; and 10 hospitals in 2009. Further, five hospitals reported a CR- KP 
proportion of more than 10% in at least one year of the study period. The five hospitals 
with the highest proportions of CR-KP were all located in the Mid-Atlantic region of the 
U.S. The total number of CR-KP isolates was calculated for all the participating 
hospitals over the study period to show the increase in these isolates over time, as 
shown in figure 4.2. 
The mean proportion of carbapenem-resistant K. pneumoniae increased by 130%, from 
a mean of 1.3% in year 2006 to a mean of 3.1% in year 2009 (P=0.003, Table 4.5, 
figure 4.3) and the mean incidence rate for carbapenem-resistant K. pneumoniae (per 
1000 patient days) increased by 120%, from 0.07 in year 2006 to 1.52 in 2009 (P 
=0.0118, table 4.6, figure 4.3). 
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Table 4.4 Changes in carbapenem-resistant K. pneumoniae over the study period 
Bacteria-resistance measure year Median IQR range 
CR-KP proportion (%) 2006 0.0 0 - 1 0 – 14 
 2007 0.0 0 - 1 0 - 20 
 2008 1.0 0 - 2 0 - 20 
 2009 1.0 0 - 2 0 - 23 
CR-KP rate (1000 PDs) 2006 0.0 0 - 0.05 0 - 1.054 
 2007 0.0 0 - 0.05 0 - 0.548 
 2008 0.02 0 - 0.06 0  - 1.002 
 2009 0.04 0 - 0.07 0 - 1.049 
CR-KP rate (1000 discharges)  2006 0 0- 0.26 0 -  5.98 
 2007 0 0 - 0.30 0  - 3.48 
 2008 0.12 0 - 0.34 0  - 6.27 
 2009 0.21 0 - 0.40 0 – 5.78 
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Figure 4.2 Total number of carbapenem-resistant K. pneumoniae isolates over the study 
period 
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Table 4.5 Changes in carbapenem-resistant K. pneumoniae proportions (%) 
Year LS means SE Lower CI 95% Upper CI 95% 
2006 1.33 0.69 -0.057 2.721 
2007 1.63 0.69 0.245 3.013 
2008 2.33 0.69 0.943 3.713 
2009 3.08 0.72 1.644 4.519 
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Table 4.6 Changes in carbapenem-resistant K. pneumoniae rates/1000 PDs 
Year LS means SE Lower  95% CI Upper 95% CI 
2006 0.07 0.03 0.002 0.138 
2007 0.06 0.03 -0.006 0.130 
2008 0.10 0.03 0.031 0.166 
2009 0.15 0.04 0.081 0.224 
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Figure 4.3 Changes in carbapenem-resistant P. aeruginosa and K. pneumoniae over 
the four years 
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4.4 Survey 
 
The response rate for the online survey was 64%. Among the thirty-two hospitals 
responded two hospitals were excluded because one hospital did not provide any 
antibiograms and the second hospital antibiograms were not including number of 
isolates. For the first part of the survey (antibiogram construction), data from previous 
projects were used.  
4.4.1 Antibiogram construction  
 
Antibiograms construction information was available for 38 hospitals out of the total 40 
hospitals included in the study. Data about antibiogram construction from another 
project were used for this study.  Multiple methods were employed in year 2009 for 
routine susceptibility testing, including MicroScan (n = 9), Vitek 2 (n = 11), disk diffusion 
(n = 5), Phoenix (n = 9), Vitek (n=3) and Sensititre (n=1). Thirty-one hospitals reported 
removing duplicate isolates from the same patient from their annual antibiograms; while 
seven hospitals included duplicates (two of them included all duplicates while the other 
five included some). Thirty-two hospitals reported that surveillance cultures were 
excluded, and six hospitals included surveillance cultures in their annual antibiograms. 
The next two sections described responses of thirty hospitals to the remaining 
components of the survey. 
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4.4.2 Carbapenem-resistant K. pneumoniae 
 
The survey results of this section are summarized in table 4.7. Twenty-seven hospitals 
reported that they have encountered clinical isolates of carbapenem-resistant 
Enterobacteriaceae including carbapenem-resistant K. pneumoniae within the past 5 
years, while three hospitals reported they had not. Of the twenty seven hospitals, 
eighteen hospitals reported their CRE isolates represented both colonized and clinical 
(caused clinical infection) organisms. Five hospitals reported that they were clinical 
isolates only, two reported they were colonizing isolates only, and two hospitals were 
not sure. The approximate rate of isolation of carbapenem-resistant Enterobacteriaceae 
(all unique isolates from individual patients) varied in 2010 among hospitals.  Around 
50% of hospitals (14 hospitals) reported an isolation rate of < 5 patients in the past year, 
seven hospitals encountered CRE in 5 - 20 patients and six hospitals reported more the 
20 patients. These isolates were from patients transferred from another hospital and /or 
long-term care facility in 12 hospitals. Thirteen hospitals were not sure of the source, 
while just two hospitals reported that these isolates were not from transferred patients. 
Microbiological tests used to identify and confirm CRE including carbapenem-resistant 
K. pneumoniae varied among hospitals. Most hospitals used imipenem, meropenem, or 
ertapenem (mainly imipenem) resistance on routine susceptibility test  to identify the 
CRE isolates and then confirmed by the following microbiological methods:  Modified 
Hodge test (n=14); PCR (n=3); E-test (n=1); Modified Hodge test and PCR (n=2); 
Modified Hodge test, Etest, and PCR (n=1); Modified Hodge test, indirect phenotypic 
test, and PCR (n=1); other (n=1).  However, four hospitals did not use any confirmatory 
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testing and relied on imipenem or meropenem resistance on routine susceptibility 
testing.  
Part of this survey was to compare if these hospital antibiograms reflected the 
approximate rate of isolation of CR-KP.  According to the survey, twenty hospitals 
reported that their antibiograms for 2009 and/or 2010 accurately reflected the 
approximate rate of isolation of CRE organisms, and they reflected the rate of isolation 
even with a small percentage.  They were asked in particular, “For example, if you 
isolate CREs ‘only rarely’, does your antibiogram show that a small percentage of 
isolates (e.g., 1 or 2%) of K. pneumoniae are resistant to imipenem or meropenem?” 
Five hospitals reported that they did not include such a percentage in their 
antibiograms.  However, four of these hospitals reported an isolation rate of less than 
five isolates in the last year which would not affect this study.  Additionally, when the 
rates obtained from antibiograms in 2009 and the rates obtained via the survey were 
compared they were highly correlated (r = 0.85, P<0.0001).  
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Table 4.7 Survey summary results: Carbapenem-resistant K. pneumoniae 
Criteria results 
CR-KP encounter 27/30 
Type of isolates Colonized & 
clinical 
(18/27) 
Clinical only 
(5/27) 
Colonized 
only 
(2/27) 
Unknown 
 
(2/27) 
Rate of isolation in 
the past year 
< 5  
(14/27) 
5-20 
(7/27) 
>20 
(6/27) 
 
Source Transferred 
from another 
hospital / 
long-term 
care facility 
(12/27) 
Not sure of 
the source 
(13/27) 
Not from 
transferred 
patients 
(2/27) 
 
Microbiology test 
used to confirm 
KPC 
MHT (14) PCR ( 3) E-test (1) MHT,PCR (2) 
MHT, PCR, 
E-test (1) 
MHT, PCR, 
indirect 
phenotypic 
test (1) 
Other (1) Routine 
susceptibility 
only ( 4) 
 
ASP Yes (24/30) No (6/30)   
ASP role in KPC Monitor & 
intervene 
(21/24) 
Don not 
monitor of 
intervene 
(3/24) 
  
Isolation 
procedures for 
infected/colonized 
patients 
(24/24)    
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4.4.3 Antimicrobial stewardship efforts  
 
Twenty-four hospitals reported having a formal ASP, while six hospitals reported not 
having an antimicrobial stewardship program in their institution.  Of the twenty-four 
hospitals, twenty-one hospitals had their antimicrobial stewardship personnel monitor 
and intervene with CRE including CR-KP infections and/or colonization cases in 
accordance with infection control personnel, whereas the other three hospitals 
antimicrobial stewardship personnel do not intervene in these cases. All of the hospitals 
reported conducting isolation procedures for patients infected or colonized with CRE 
including CR-KP and implementing strict infection control measures. Most of the CRE 
cases were handled on a case-by-case basis.  Finally, more than half of the responders 
reported no significant changes in their antimicrobial stewardship activities/program 
during the years 2006-2009. The other hospitals reported significant improvements in 
the enforcement of their ASP activities. 
One of the survey questions was about the restriction policy of carbapenems. A total of 
19 hospitals responded that they restricted carbapenems.  Of these, eleven hospitals 
had restriction policies that entailed a preauthorization requirement.  A preauthorization 
restriction policy was one in which prior approval was required by either pharmacy or 
medical personnel before the carbapenem agent was dispensed for at least some 
patient populations.  The other eight hospitals stated that they restricted carbapenems, 
but did not require preauthorization.  For example, a restriction policy may entail that a 
carbapenem could be dispensed upon a physician order provided appropriate criteria 
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for use were met, such as febrile neturopenia, but the restriction policy did not require 
preauthorization or confirmation that the carbapenem order met the usage criteria 
before the drug was released from the pharmacy.     
It was not known how long the restriction policy had been implemented; thus, 2009 
mean carbapenem use and CR-PA rates and proportions were compared for hospitals 
that did (n = 19) vs. those that did not restrict carbapenems (n =11), as displayed in 
table 4.8.  Although carbapenem use was lower in hospitals that restricted 
carbapenems, there were not any statistical differences in either CR-PA and CR-KP 
rates or proportions for 2009. 
 
Table 4.8 Carbapenem use (DOT/1000PDs) and resistance based on restriction status 
of carbapenems in 29 hospitals in 2009  
 Restriction  No restriction  Wilcoxon rank test p-value 
Carbapenems Mean ±SD Mean ±SD  
 34.96 ±19.53 62.05 ± 26.58 0.0111 
CR-PA rate (1000 PDs) Mean ±SD Mean ±SD  
 0.75 ± 0.42 0.96 ±0.75 0.4568 
CR-PA proportion (%) Mean ±SD Mean ±SD  
 17 ± 5 19 ± 7 0.6523 
 one hospital data was excluded. 
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4.5 Carbapenem-resistant P. aeruginosa rates/1000 PDs explanatory 
model 
 
A GEE model utilizing normal distribution and identity link was fitted to explain CR-PA 
rates/1000 PDs. The model (with lowest QICu) to explain CR-PA rates included the 
variables of fluoroquinolone use (ciprofloxacin, levofloxacin, gatifloxacin), carbapenem 
use (imipenem, meropenem, doripenem), antipseudomonal penicillin use, and 
antipseudomonal cephalosporin use.  Most of the other proposed models had a very 
similar QICᵤ score to the best model, ∆QICᵤ =1.0. The full model had a ∆QICᵤ =3.0 from 
the best model. Hence, the simplest model identified above was chosen model to 
explain CR-PA rates as shown in table 4.9.  According to the GEE analysis, none of the 
antipseudomonal antibiotics included in the model were associated significantly with 
CR-PA rates/1000 PDs. 
After selecting the model, adjusting for each of the potential confounders (hospital bed 
size, CMI, aminoglycoside use, and hospital geographical location) was conducted. The 
change in the parameter estimates were less than 1% after adding bed size, less than 
10% after adding aminoglycosides, and ≥ 20% after adding, CMI, and geographical 
location. Consequently, the last two confounding variables were added to the model and 
the adjusted parameter estimates are displayed in table 4.10. According to the GEE 
analysis, none of the antipseudomonal antibiotics included in the model were 
associated significantly with CR-PA rates/1000 PDs. 
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Table 4.9 GEE analysis with carbapenem-resistant P. aeruginosa rates/1000 PDs as 
the dependent variable (crude estimates) 
Parameter β SE Z P value 
Intercept 1.015 0.257 3.94 <0.0001 
Flourquinolines 0.002 0.001 1.51 0.1305 
Carbapenems -0.002 0.004 -0.52 0.6007 
Antipseudomonal 
cephalosporins 
-0.0004 0.003 -0.16 0.8750 
Antipseudomonal 
penicillins 
-0.002 0.00 -1.55 0.1220 
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Table 4.10 GEE analysis with carbapenem-resistant P. aeruginosa rates/1000 PDs as 
the dependent variable (adjusted estimates).  
Parameter β SE Z P value 
Intercept -0.693 0.850 -0.81 0.4151 
Carbapenems -0.004 0.0034 -1.25 0.2093 
Fluoroquinolones 0.002 0.0014 1.53 0.1250 
Antipseudomonal cephalosporins -0.001 0.0022 -0.28 0.7827 
Antipseudomonal penicillins -0.003 0.0018 -1.57 0.1171 
CMI 1.099 0.551 1.99 0.0461 
Geographical region 
(Mid-Western vs. Mid-Atlantic) 
0.1004 0.356 0.28 0.7780 
Geographical region 
(Mid-Continent vs. Mid-Atlantic) 
0.1429 0.316 0.45 0.6506 
Geographical region 
(Southeastern vs. Mid-Atlantic) 
-0.1672 0.279 0.60 0.5488 
Geographical region 
(Western vs. Mid-Atlantic) 
-0.0503 .387 -0.13 0.8967 
Geographical region 
(New-England vs. Mid-Atlantic) 
-0.209 0.555 -0.38 0.7063 
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The steps that were performed after selecting the persimmons model were repeated, 
but with the proportion of patients in each of the four APR-DRG grouper scores.  The 
model (with lowest QICᵤ) to explain CR-PA rates included the variables of 
fluoroquinolone use (ciprofloxacin, levofloxacin, gatifloxacin), carbapenem use 
(imipenem, meropenem, doripenem), antipseudomonal penicillin use, and 
antipseudomonal cephalosporin use. This was followed by adjusting for potential 
confounders (hospital bed size, aminoglycoside use, hospital geographical location, and 
APR-DRG scores proportions). Consequently, the APR-DRG groups and geographical 
location were added to the model, and the adjusted parameter estimates are displayed 
in table 4.11.  According to GEE analysis, there was no significant association between 
CR-PA rates/ PDs and any of the variables proposed by the model. 
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Table 4.11 GEE analysis with carbapenem-resistant P. aeruginosa rate/1000 PDs as 
the dependent factor and APR-DRG independent variables (adjusted estimates) 
Parameter β SE Z  P value 
Intercept 1.103 1.067 1.03 0.3015 
 Antipseudomonal cephalosporins -0.003 0.002 -1.39 0.1647 
Carbapenems -0.004 0.004 0.90 0.3674 
Fluoroquinolones 0.002 0.002 1.23 0.2169 
Antipseudomonal cephalosporins  -0.001 0.003 -0.31 0.7549 
Geographical region 
(Mid-Western vs. Mid-Atlantic) 
0.057 0.362 0.16 0.8755 
Geographical region 
(Mid-Continent vs. Mid-Atlantic) 
0.080 0.338 0.24 0.8139 
Geographical region 
(Southeastern  vs. Mid-Atlantic) 
-0.116 0.275 -0.42 0.6729 
Geographical region 
(Western  vs. Mid-Atlantic) 
0.007 0.350 0.02 0.9837 
Geographical region 
(New-England vs. Mid-Atlantic) 
-0.183 0.524 -0.35 0.7268 
APR-DRG proportions 
 (base-minor) 
Extreme 2.640 5.779 0.46 0.6478 
Major -0.669 2.324 -0.29 0.7736 
Moderate -0.113 2.542 -0.04 0.9645 
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4.6 Carbapenem-resistant P. aeruginosa proportion explanatory 
model 
 
A GEE model utilizing binomial distribution and logit link was fitted to explain CR-PA 
proportions. The model (with lowest QICᵤ) to explain variability in CR-PA proportions 
included the variables of fluoroquinolone use, carbapenem use, and antipseudomonal 
cephalosporin use.  The second best model had a QICᵤ score close to the best model, 
∆QICᵤ 2.15, and included antipseudomonal penicllins in addition to the variables 
identified in the previous model. Using the principle of parsimony, the model with the 
lowest QICᵤ and fewest explanatory variables was selected. According to the GEE 
analysis, none of the antipseudomonal antibiotics included in the model were 
associated significantly with CR-PA proportions over the study period as displayed in 
table 4.12. 
 Each of the potential confounding variables (case mix index, bed size, geographical 
location, aminoglycoside use, and antipseudomonal penicillins) was adjusted for in a 
similar fashion to the method used in section 4.5.  Table 4.13 represents the parameter 
estimates for the adjusted explanatory model. The parameter estimates were 
exponentiated for interpretation purposes.  According to the GEE analysis, none of the 
antipseudomonal antibiotics included in the model were associated significantly with 
CR-PA proportions over the study period. 
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Table 4.12 GEE analysis with carbapenem-resistant P. aeruginosa proportions as the 
dependent variable (crude estimates) 
Parameter β Exp(β) SE Z P value 
Intercept -1.508 0.221 0.172 -8.76 <0.0001 
Carbapenems 0.003 1.003 0.003 0.97 0.3317 
Fluoroquinolones 0.002 1.002 0.001 1.14 0.2524 
Antipseudomonal 
cephalosporins 
-0.002 0.998 0.003 -0.42 0.6737 
 
 
  
80 
 
Table 4.13 GEE analysis with carbapenem-resistant P. aeruginosa proportion as the 
dependent variable (adjusted estimates) 
Parameter β Exp(β) SE Z P value 
Intercept -2.451 0.086 0.668 -3.67 0.0002 
Carbapenems 0.004 1.004 0.003 1.26 0.2076 
Fluoroquinolones 0.002 1.002 0.001 1.48 0.1388 
Antipseudomonal cephalosporins -0.003 0.997 0.002 -1.29 0.1974 
Antipseudomonal penicillins -0.003 0.997 0.002 -2.02 0.0437 
CMI 0.703 2.020 0.463 1.52 0.1291 
Geographical region 
(Mid-Continent vs. Mid-Western) 
0.342 1.408 0.211 1.62 0.1051 
Geographical region 
(Southeastern vs. Mid-Western) 
-0.337 0.714 0.257 -1.31 0.1900 
Geographical region 
(Mid-Atlantic vs. Mid-Western) 
0.295 0.745 0.223 1.16 0.2455 
Geographical region 
(Western vs. Mid-Western) 
-0.343 0.710 0.182 -1.88 0.0596 
Geographical region 
(New-England vs. Mid-Western) 
-0.209 0.811 0.191 -1.10 0.2733 
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4.7 Carbapenem-resistant K. pneumoniae explanatory model 
 
A GEE model utilizing a binomial distribution and logit link was used to model CR-KP. 
The best model for explaining CR-KP isolates presence in the 40 hospitals included the 
variables of carbapenem use, fluoroquinolone use, aminoglycoside use, 
antipseudomonal penicillins, and hospital geographical location. The second best model 
had a QICᵤ score very similar to the best model, ∆QICᵤ 1.80, and included carbapenem 
use, fluoroquinolone use, third-and forth-cephalosporin use, aminoglycoside use, 
antipseudomonal penicillins, and geographical location. Using the principle of 
parsimony, the model with lowest QICᵤ and fewest explanatory variables was preferred. 
The parameter estimates were exponentiated for interpretation purposes  
After selecting the "best" model, it was adjusted for the potential confounders (bed size, 
CMI, third-and fourth-generation cephalosporins) similar to the method used in section 
4.5. None of the confounding variables changed the parameter estimate by more than 
20%; hence, the crude estimates were used. Table 4.14 represents the parameter 
estimates for the explanatory model. 
According to GEE analysis, carbapenem antibiotic use was significantly (P=0.0149) 
associated with the presence of CR-KP isolates. Thus, the estimated change in the 
odds of carbapenem-resistant K. pneumoniae for a one-unit increase in carbapenem 
antibiotic use is 1.04 with a 95% confidence interval of (1.02, 1.06). This means that for 
ten DOT/1000 PDs increase in carbapenem use, the odds of carbapenem-resistant K. 
pneumoniae isolation increase by 42%.  Hospitals located in the Midwestern, 
Midcontinent, Western, and New -England regions of the nation were less likely to 
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encounter CR-KP isolates when compared to hospitals located in the Mid-Atlantic 
region of the nation (P = 0.0002, 0.0140, 0.0001, 0.0304, respectively). 
Finally, antipseudomonal penicillin use was significantly associated with CR-KP 
isolation (P=0.0477). Thus, the estimated change in the odds of carbapenem-resistant 
K. pneumoniae for a one unit increase in antipseudomonal penicillin antibiotic use is 
0.985 with 95% confidence interval of (-0.0298,-0.0002). This means that for a ten DOT/ 
1000 PDs increase in antipseudomonal penicillin use, the odds of CR-KP isolation 
decreased by 14%. 
83 
 
Table 4.14 GEE analysis with carbapenem-resistant K. pneumoniae as the dependent 
variable 
Parameters β Exp(β) SE Z score P value 
Intercept 4.002 54.407 1.477 2.71 0.0067 
Carbapenems 0.035 1.036 0.014 2.43 0.0149 
Fluoroquinolones -0.009 0.991 0.006 -1.63 0.1033 
Antipseudomonal Penicillins  -0.015 0.985 0.008 -1.98 0.0477 
Aminoglycosides -0.053 0.948 0.027 -1.93 0.0537 
Geographical region 
(Mid-Western vs. Mid-Atlantic) 
-2.922 0.054 0.779 -3.75 0.0002 
Geographical region 
(Mid-Continent vs. Mid-Atlantic) 
-2.688 0.068 1.049 -2.56 0.0140 
Geographical region 
(Southeastern vs. Mid-Atlantic) 
-0.781 0.458 0.968 -0.81 0.4199 
Geographical region 
(Western  vs. Mid-Atlantic) 
-4.399 0.012 1.138 -3.86 0.0001 
Geographical region 
(New-England vs. Mid-Atlantic) 
-3.057 0.047 1.413 -2.16 0.0304 
*bolded = P value < 0.05 
84 
 
CHAPTER 5 
Discussion 
 
5.1 Summary of findings 
 
This chapter summarizes the study, providing a discussion of the study results, 
conclusions, limitations, and suggestions for future research. 
In this current investigation, it was attempted to explain carbapenem-resistant 
Pseudomonas aeruginosa and Klebsiella pneumoniae in a consortium of academic 
medical centers over the period from 2006-2009.  
Objective 1 described trends of antimicrobial use in 40 hospitals over the study period. 
Total broad spectrum antibiotics for five classes of gram-negative antibiotics increased 
over time. Carbapenem and piperacillin-tazobactam use increased by 25%, while 
fluoroquinolone and aminoglycoside use decreased over time.   
Objective 2 described rates and proportions of CR-PA and showed rates and 
proportions of CR-PA to be stable over four years. 
Objective 3 described rates, proportions, and number of CR-KP and showed an 
increase of CR-KP over the four-year period. Moreover, the CR-KP isolation rate, 
isolation procedure, source, microbiological identification techniques, and isolation rate 
were described in thirty hospitals via a survey. CR-KP rates obtained from antibiograms 
were strongly correlated with rates obtained by the survey. Hospitals conducted strict 
measures with regard to isolation of such organisms. 
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Objective 4 identified important predictors of CR-KP isolation within the 40 participating 
hospitals over four-year period among broad spectrum gram-negative antibiotic classes, 
CMI, and hospital demographics (bed size, geographical location). The GEE analysis 
utilizing binary distribution and logit link showed a significant association between 
hospital geographical location and carbapenem use, and antipseudomonal penicillin 
use. However, no significant predictors were associated with CR-PA rates/1000 PDs or 
proportions over the study period. 
 
5.2 Discussion of results by objective 
 
Objective 1 
Descriptive statistics were used to assess current broad spectrum gram-negative 
antibiotic use in U.S. academic medical centers. The observations of this investigation 
are updated and consistent with prior investigation of antibiotic use in UHC consortium 
of hospitals from 2002 to 2006 conducted by Pakyz et al.[48]  The previous investigation 
showed a 59% increase in carbapenem use and an 84% increase in the use of 
piperacillin-tazobactam between 2002 and 2006. However, this investigation showed a 
lower rate of increase in carbapenem use and piperacillin-tazobactam over the period of 
2006 to 2009, 24% and 25% respectively. Further exploration assessed 19 hospitals 
that restricted carbapenem use and found they used less carbapenems than hospitals 
that did not restrict carbapenems, but had a significant (P=.0001) increase in 
carbapenem use, from 29.31 DOT/1000 PDs in 2006 to 39.80 DOT/1000 PDs in 2009. 
Carbapenem use increased presumably because of increasing resistance among gram-
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negative organisms, including ESBLs producing Enterobacteriaceae, to other more 
commonly used antimicrobial agents.[124, 125]  The proportion of piperacillin-
tazobactam use was similar to the proportion of total third-and fourth-generation 
cephalosporin use. Fluoroquinolone use decreased slightly over the study period; 
however, they remained the most commonly prescribed class of antibiotics among 
broad spectrum antimicrobials throughout the study period. The previous investigation 
showed stability in fluoroquinolone use over 2002 -2006; however, this investigation 
includes twice as many hospitals. Similar to Pakyz et al., third- and fourth-generation 
cephalosporin use did not change during the study period. Finally, aminoglycoside use 
was decreasing in the current study sample. 
 
Objective 2 
 In the current investigation, rates and proportions of CR-PA remained stable or even 
declined over four years, while the mean use of carbapenems increased. This 
observation is supported by similar recent investigation of CR-PA proportion over six 
years in 25 hospitals.[47]  CR-PA resistance is stable over time, although carbapenem 
use is increasing over the same period. However, most of these organisms are 
multidrug resistant, and the contributions of other antibacterial compounds to their 
prevalence remains to be fully explained.[50]  In the same context, when hospitals 
which restricted the availability of carbapenem antibiotics were compared to those 
which did not restrict, it was found that hospitals restricted carbapenem used 
significantly less than hospitals that did not restrict use, but restriction was not 
associated with lower rates of CR-PA.  
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 Objective 3 
The rates and proportions of CR-KP varied among the participating hospitals in this 
investigation. Proportions and rates of CR-KP increased by 120% and 130%, 
respectively, between 2006 and 2009. However, the magnitude of this increase varied 
considerably among hospitals, as some hospitals reported outbreaks (more than100 
isolate per year), while some hospitals reported the isolation of less than 5 isolates.  
However, this observation is not consistent with the MYSTIC report that found the 
incidence of KPC to be declined in 2008 compared to the steep increase in resistance 
rates observed from 2004 to 2007 [71].  This is likely due to the larger number of 
participating hospitals of this investigation compared to the MYSTIC report (40 vs. 15). 
Furthermore, the CDC reported, as of December 2010, that KPC-producing isolates 
have been received or identified from 36 states, which indicates the spread of these 
organisms. [28,36]  Carbapenem-resistant K. pneumoniae is the most common 
carbapenem-resistant Enterobacteriaceae in the United States. Based on the survey 
results for 30 hospitals, antibiograms were found to reflect the approximate rate of 
isolation of CR-KP, specifically, both rates from antibiograms and the survey were 
highly correlated for 2009.  Almost one half of the responders confirmed the isolation of 
CRE to be of transferred patients from another hospital and/or long-term care facility 
which is the true case in most outbreaks reported as patients come to the hospital from 
another healthcare facility carrying these organisms.  However, the other half of the 
responders were not sure about the source of CRE isolates; these could be from 
hospital patients.  The presence of CR-KP carriage has been described in a number of 
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studies involving patients from long-term acute care hospitals.[126-128]  One 
investigation found that more than half of the patients with carbapenem-resistant gram-
negative bacteria were admitted from post-acute care facilities implying that these 
health-care settings may be significant reservoirs for transmission and spread of these 
bacteria. [127]  According to the survey results, most of the hospital’s CRE isolates 
were both colonizing and clinical isolates which can occur with the presence of a small 
number of CR-KP clinical cases. For example, one investigation of three patients with 
CR-KP infection transferred from long-term acute care hospital showed that 49% of the 
residents were having colonized with CRE isolates.[27]  The majority of the hospitals 
used phenotypic method along with the imipenem (in some hospitals meropenem or 
ertapenem) resistance routine susceptibility test to confirm CR-KP.  Modified Hodge test 
was the most common confirmatory technique used either alone, or in combination with 
other techniques, mainly PCR method.  Although the CLSI recommendation to change 
(lower) carbapenem breakpoints were corrected in 2010, it appears that hospitals’ 
microbiology laboratories continue to depend on the older breakpoints in addition to 
phenotypic confirmatory tests (e.g. MHT). This is likely due to the delay in the Food and 
Drug Administration (FDA) approval process, consequently the automated system 
manufacturers have not been able been able to provide microbiology laboratories with 
validated equipments with the new CLSI breakpoints.[129]  However, with the lowering 
of the carbapenem breakpoints and exclusion of the need to perform MHT testing, it 
remains questionable whether some patients colonized/infected with carbapenemase-
producing organisms might be missed. [129] 
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One item that all hospitals were consistent about is the requirement for universal 
precautions and infection control measures including patient isolation being performed 
as early as colonized or infected patients with CRE were identified. Strict infection 
control measures have been shown to decrease and contain the spread and the 
incidence of CRE in many outbreaks. [88-90] 
Objective 4 
Carbapenem-resistant K. pneumoniae  
The determinants of bacterial resistance are complex and multifactorial; no single 
comprehensive model explaining resistance has yet been developed. This investigation 
used generalized estimating equations (GEE) with binary distribution and logit link to 
examine the relationship between some potential predictor variables, in particular 
aggregated antimicrobial drug use, SOI (CMI), hospital demographics, and aggregated 
carbapenem-resistance in clinical isolates of K. pneumoniae in a consortium of UHC 
university teaching hospitals. CR-KP is resistant to most available antibiotic drugs, 
leaving few options such as colistin or tigecycline, which are more toxic and possibly 
less effective. [21, 26, 76]  Infections with CR-KP are associated with poor outcomes 
and a high mortality rate.[22,28,29]  The results of this investigation showed that 
carbapenem antibiotic use, geographical location, and antipseudomonal penicillins were 
significantly associated with CR-KP isolation, with carbapenem use being positively 
associated with CR-KP isolation.  While there was no ecological study at the hospital 
level to compare the findings with, this observation was in general agreement with other 
single center case control studies in which prior carbapenem use was identified as an 
independent risk factor for the isolation of CR-KP.[22, 29, 42, 43, 44]  This investigation 
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observed a significant increase in CR-KP rates and proportions over the period of 2006 
to 2009 in a relatively large sample of US hospitals. Carbapenem use continued to 
increase in the same set of hospitals over the study period. This increase is likely due to 
the wide use of carbapenems for the treatment of severe infections caused by ESBL 
producing Enterobacteriaceae including K. pneumoniae as carbapenems considered 
the drug of choice in these infections. Carbapenems have been broadly used to treat 
Enterobacteriaceae species which may increase antibiotic selection pressure, 
consequently promoting carbapenem-resistance bacteria development.[51-53]  The 
specific mechanisms of CR-KP include production of KPC, metallo-beta-lactamases and 
loss of porins as described in detail in chapter 2, section 2.5. This investigation included 
all CR-KP isolates, regardless of the mechanism of resistance as this information could 
not be obtained. Therefore, the variation in resistance mechanisms, which may be 
associated with different risk factors among the CR-KP isolates, could not be 
incorporated in the model to better clarify the role of carbapenem use in the isolation of 
CR-KP.  Additionally, hospital geographical location was identified as an independent 
predictor of the CR-KP isolation.  Hospitals located in the Mid-Atlantic region were more 
likely to encounter CR-KP isolation when compared to hospitals located in the 
Midwestern, Mid-Continent, Western, and New-England regions of the continental U.S.  
The first KPC producing isolate was identified in North Carolina in 2001. Reports soon 
followed from other regions of the U.S., mostly on the East Coast. Subsequently, the 
escalating prevalence of CR-KP infection in the Mid-Atlantic costal region of the United 
States was documented and some of these sporadic outbreaks have turned into an 
endemic spread.[30-32]  The CDC reported as of December 2010, that KPC-producing 
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isolates have been received or identified from 36 states.[36]  Hospitals located in the 
Southeastern region were not different from the Mid-Atlantic region indicating the 
endemic spread of these isolates in this region.  
The antipseudomonal penicillins and CR-KP association was in a negative direction, 
implying a favorable effect of the increase in the use of antipseudomonal penicillins 
(mainly piperacillin-tazobactam) on CR-KP. The favorable impact of agents like 
piperacillin-tazobactam on CR-KP could imply that hospitals using more piperacillin-
tazobactam could be using less of other classes of antibiotics with known effect on CR-
KP.  CMI and APR-DRG categories were not part of the final model to explain CR-KP 
isolation, but adjusting for each of them was considered. However, when they were 
forced into the model, there was no significant association with CR-KP isolation. 
Carbapenem-resistant P.aeruginosa 
This investigation used generalized estimating equations (GEE) to examine the 
relationship between some potential predictor variables, in particular aggregated broad 
spectrum antipseudomonal antimicrobial drug use, SOI (CMI, APR-DRG), hospital 
demographics and aggregated carbapenem-resistance P. aeruginosa in a consortium of 
UHC university teaching hospitals. Binomial distribution and logit link were used to 
model carbapenem-resistant P. aeruginosa proportions; normal distribution and identity 
link were used to model carbapenem-resistant P. aeruginosa rates/1000 PDs. The 
results of this investigation showed no significant association between CR-PA 
rates/1000 PDs, proportions, and any of the predictors identified in each model. 
Previous single center case control studies identified prior carbapenem use, 
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fluoroquinolone use, and extended-spectrum cephalosporins as risk factors for CR-PA; 
however, none of the other antipseudomonal antibiotic classes identified in the model 
selection process were significantly associated with CR-PA proportions and rates. 
Similarly, Eagye et al. found no significant association between carbapenem use, 
fluoroquinolone use, and CR-PA incidence rates in a multivariable model in 25 
hospitals. [47] 
Finally, when CMI was forced into the model as a predictor, there was a positive 
association with CR-PA rates/1000 PDs.  Hospitals with an elevated CMI have sicker 
patients and perform more complicated procedure. Also, none of the APR-DRG 
categories were associated with CR-PA rates or proportions when forced into the 
model. 
5.2 Limitations 
First, the current study design is a longitudinal ecological study. Using an ecological 
approach has some limitations. By definition, ecologic data contain only marginal 
observations on the common distribution of individually defined confounders and 
outcomes.[130]  “Ecological fallacy” occurs when the results of an ecological study are 
interpreted as being applied to individuals.[131]  In this current investigation, the role of 
aggregated antibiotic use on carbapenem-resistant gram-negative bacteria in U.S. 
academic hospitals was assessed; the resulting findings do not necessarily reflect to the 
patient level.  Ecological (hospital-level) variables weaken the linkage between patient-
level variables including outcome, exposure, and covariates, and may result in a 
complex misrepresentation at the patient-level.  For example, if this same project was 
conducted with patient-level data, stronger linkages would be found compared to 
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ecological study results.[91]  According to Harbarth et al., ecological studies in general 
can identify trends, but lack sufficient details to make the case for causality between 
antibiotic exposure and resistance in gram-negative bacteria.  He suggested including 
patient-level data analysis in these studies to provide more valid results.[131]  In 
contrast, Turnidge et al. stated that “given the complexity of resistance 
ecology…….when correlations are shown they are almost certainly of major importance 
and suggest that reduction in consumption of the correlated antibiotic class will reduce 
resistance”.[132]  Despite the limitations of ecological studies there was adjustments for 
some confounders.  
Second, the response rate for the survey or antibiogram requests was not 100%. It is 
possible that those that did not respond to the survey would have different patterns of 
antibacterial drug use and/or carbapenem-resistance.  However, the non-responding 
hospitals had similar demographic characteristics to responding hospitals; the mean 
bed size, CMI, and patient age were similar among responders and non-responders. 
The non-respondent rate can be explained, in part, due to changes in the infectious 
diseases clinical pharmacists or physicians positions over the study period.  A contact 
from previous studies is more likely to respond compared to a new clinical pharmacist, 
who may not be aware of the UHC CRM database.  
 
Third, this investigation used aggregated data at the hospital-level including aggregated 
susceptibility data obtained from whole-house annual antibiograms. The literature is 
conflicting as to whether antibiograms are truly reflective of nosocomial resistance 
rates.[133,134]  However, a network of hospitals such as described in this investigation 
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may be able to link changes in antimicrobial drug use to changes in resistance using 
whole-house antibiograms because of greater statistical power and the potential to 
adjust for confounders and some methodological differences in antibiogram reporting 
methods. This interpretation is supported by the findings from a MYSTIC surveillance 
project. [135]  In 10 -15 medical centers observed over a 3 year period, significant 
positive relationships in aggregated mean drug use and antimicrobial resistance rates 
were observed for a number of “drug-bug” pairs. However, at the institution level no 
significant relationships were observed.  Although additional research is necessary to 
determine if this approach is valid, this investigation and the limited available data 
suggest that results from annual antibiograms correlate well to more established 
surveillance programs. [134,136]  
Additionally, there was variability between hospitals with respect to the method of 
measuring susceptibility to carbapenem antibiotics. While most hospitals used CLSI 
breakpoints to determine susceptibility, the source of clinical isolates between hospitals 
was likely to be variable depending upon, for example, the number of specimens 
obtained from outpatients and the proportion of cultures obtained from pediatric 
patients.  Additionally, while most hospitals did not include surveillance cultures in the 
antibiogram and most deleted duplicate cultures from the same patients, this was not 
always the case. Within a hospital, these sources of variability may be acceptable since 
the practice is likely to be consistent, but these differences limit the ability to compare 
across hospitals. However, the incorporation of some antibiogram construction data 
(e.g. removal of duplicates, surveillance cultures) as covariates did not change the 
results of this investigation. 
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Fourth, hospital infection control measures and the impact of patient-to-patient 
transmission were not measured. Patients infected with MDR bacteria from another 
hospital may impact the resistance rate in that hospital.[126-128] 
Finally, this study used hospital data from the UHC. Secondary databases can be 
convenient since the researcher does not have to wait for the data to be prospectively 
collected.  However, problems with inadequate or inaccurate codes in databases may 
introduce bias in the results.[137,138]  While potential predictors were considered, there 
may be other factors that influence the prediction of carbapenem-resistant bacteria that 
were not available.  Factors such as non-formulary antibiotic drug use, antimicrobial 
combination therapy, and infection control measures cannot be assessed, as the UHC 
database does not capture such information. Hence, these factors which contribute to 
drug use and bacterial resistance were not included in the study. Further, the UHC 
consists of all-payer hospital discharge data from most of the United Sates academic 
medical centers. However, community hospitals are not represented.  
  
5.4 Future research 
 
This study provides the basis for some potential future research. While, many of these 
findings were in agreement with other studies identified, some of the findings were not. 
The modifiable risk factors identified in this investigation could be a potential target of 
intervention by antimicrobial stewardship programs.  Further, future studies that adopt a 
multilevel approach would provide a better understanding between antibiotic use and 
bacterial resistance. A multilevel approach takes into consideration the nested 
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hierarchies of data and allows integration of observations on all available levels: 
physiological (which examines exposures and responses of systems within individuals); 
individual (which examines exposures and responses of individuals); and aggregate or 
contextual (which examines exposures and responses of aggregates or clusters of 
individuals, such as hospitals).[130,139] Incorporation of patient-level data, including 
microbiology data, would potentially provide a better explanation of resistance.[131] 
 
5.5 Conclusions 
 
The results of this investigation did not show significant relationships between 
antipseudomonal antibacterial drug use and rates or proportions of carbapenem-
resistant clinical isolates of P. aeruginosa in 40 UHC academic medical centers over a 
four-year period. However, continued examination of these relationships will remain 
important since both antibacterial drug use and resistance among many clinical isolates 
will continue to evolve over time, although the direction is unclear and the 
interrelationships are currently uncertain.  The increasing spread of carbapenem-
resistant K. pneumoniae over time and across different regions of the U.S., and the 
significant relationship between carbapenem antibiotics use and carbapenem-resistant 
K. pneumoniae, emphasize the challenges associated with the treatment of multidrug- 
gram-negative bacteria.  
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